Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2959170,Clearance rate (Cl),"Clearance rate (Cl) was 6.7 +/- 6.1 ml.kg-1.min-1 (+/- SD) in neonates, which was significantly lower than the values of 18.1 +/- 2.7, 16.9 +/- 3.2, and 13.1 +/- 3.6 ml.kg-1 min-1 observed in infants, children, and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),[ml] / [kg·min],6.7,925,DB00708,Sufentanil
,2959170,Clearance rate (Cl),"Clearance rate (Cl) was 6.7 +/- 6.1 ml.kg-1.min-1 (+/- SD) in neonates, which was significantly lower than the values of 18.1 +/- 2.7, 16.9 +/- 3.2, and 13.1 +/- 3.6 ml.kg-1 min-1 observed in infants, children, and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),[ml] / [kg·min],18.1,926,DB00708,Sufentanil
,2959170,Clearance rate (Cl),"Clearance rate (Cl) was 6.7 +/- 6.1 ml.kg-1.min-1 (+/- SD) in neonates, which was significantly lower than the values of 18.1 +/- 2.7, 16.9 +/- 3.2, and 13.1 +/- 3.6 ml.kg-1 min-1 observed in infants, children, and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),[ml] / [kg·min],16.9,927,DB00708,Sufentanil
,2959170,Clearance rate (Cl),"Clearance rate (Cl) was 6.7 +/- 6.1 ml.kg-1.min-1 (+/- SD) in neonates, which was significantly lower than the values of 18.1 +/- 2.7, 16.9 +/- 3.2, and 13.1 +/- 3.6 ml.kg-1 min-1 observed in infants, children, and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),[ml] / [kg·min],13.1,928,DB00708,Sufentanil
,2959170,volume of distribution at steady state (Vdss),"The volume of distribution at steady state (Vdss) was 4.15 +/- 1.0 L/kg in neonates, significantly greater than the values of 2.73 +/- 0.5 and 2.75 +/- 0.5 L/kg observed in children and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),[l] / [kg],4.15,929,DB00708,Sufentanil
,2959170,volume of distribution at steady state (Vdss),"The volume of distribution at steady state (Vdss) was 4.15 +/- 1.0 L/kg in neonates, significantly greater than the values of 2.73 +/- 0.5 and 2.75 +/- 0.5 L/kg observed in children and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),[l] / [kg],2.73,930,DB00708,Sufentanil
,2959170,volume of distribution at steady state (Vdss),"The volume of distribution at steady state (Vdss) was 4.15 +/- 1.0 L/kg in neonates, significantly greater than the values of 2.73 +/- 0.5 and 2.75 +/- 0.5 L/kg observed in children and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),[l] / [kg],2.75,931,DB00708,Sufentanil
,2959170,elimination half-life (T1/2 beta),"The elimination half-life (T1/2 beta) was 783 +/- 346 min in neonates, significantly longer than the values of 214 +/- 41, 140 +/- 30, and 209 +/- 23 min observed in infants, children, and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),min,783,932,DB00708,Sufentanil
,2959170,elimination half-life (T1/2 beta),"The elimination half-life (T1/2 beta) was 783 +/- 346 min in neonates, significantly longer than the values of 214 +/- 41, 140 +/- 30, and 209 +/- 23 min observed in infants, children, and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),min,214,933,DB00708,Sufentanil
,2959170,elimination half-life (T1/2 beta),"The elimination half-life (T1/2 beta) was 783 +/- 346 min in neonates, significantly longer than the values of 214 +/- 41, 140 +/- 30, and 209 +/- 23 min observed in infants, children, and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),min,140,934,DB00708,Sufentanil
,2959170,elimination half-life (T1/2 beta),"The elimination half-life (T1/2 beta) was 783 +/- 346 min in neonates, significantly longer than the values of 214 +/- 41, 140 +/- 30, and 209 +/- 23 min observed in infants, children, and adolescents, respectively.",Sufentanil pharmacokinetics in pediatric cardiovascular patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2959170/),min,209,935,DB00708,Sufentanil
,2968186,distribution (alpha),"A biexponential equation provided the best fit of the sufentanil concentration data with mean +/- SEM distribution (alpha) and elimination (beta) half-lives of 2.9 +/- 1.3 and 176 +/- 87 minutes, respectively.",Pharmacokinetics of sufentanil in patients undergoing renal transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2968186/),min,2.9,1227,DB00708,Sufentanil
,2968186,elimination (beta) half-lives,"A biexponential equation provided the best fit of the sufentanil concentration data with mean +/- SEM distribution (alpha) and elimination (beta) half-lives of 2.9 +/- 1.3 and 176 +/- 87 minutes, respectively.",Pharmacokinetics of sufentanil in patients undergoing renal transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2968186/),min,176,1228,DB00708,Sufentanil
,2968186,Vc,"The mean Vc and Vd beta values were 0.15 +/- 0.05 L.kg-1 and 0.85 +/- 0.16 L.kg-1, respectively; plasma drug clearance was 11.5 +/- 3.7 ml.kg-1.min-1.",Pharmacokinetics of sufentanil in patients undergoing renal transplantation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2968186/),[l] / [kg],0.15,1229,DB00708,Sufentanil
,2968186,Vd beta,"The mean Vc and Vd beta values were 0.15 +/- 0.05 L.kg-1 and 0.85 +/- 0.16 L.kg-1, respectively; plasma drug clearance was 11.5 +/- 3.7 ml.kg-1.min-1.",Pharmacokinetics of sufentanil in patients undergoing renal transplantation. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2968186/),[l] / [kg],0.85,1230,DB00708,Sufentanil
,2968186,plasma drug clearance,"The mean Vc and Vd beta values were 0.15 +/- 0.05 L.kg-1 and 0.85 +/- 0.16 L.kg-1, respectively; plasma drug clearance was 11.5 +/- 3.7 ml.kg-1.min-1.",Pharmacokinetics of sufentanil in patients undergoing renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2968186/),[ml] / [kg·min],11.5,1231,DB00708,Sufentanil
,2968186,K10,"Mean values for K10, K12 and K21 were 0.15 +/- 0.06.min-1, 0.4 +/- 0.14.min-1 and 0.1 +/- 0.04.min-1, respectively.",Pharmacokinetics of sufentanil in patients undergoing renal transplantation. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2968186/),,0.15,1232,DB00708,Sufentanil
,2968186,K12,"Mean values for K10, K12 and K21 were 0.15 +/- 0.06.min-1, 0.4 +/- 0.14.min-1 and 0.1 +/- 0.04.min-1, respectively.",Pharmacokinetics of sufentanil in patients undergoing renal transplantation. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2968186/),1/[min],0.4,1233,DB00708,Sufentanil
,2968186,K21,"Mean values for K10, K12 and K21 were 0.15 +/- 0.06.min-1, 0.4 +/- 0.14.min-1 and 0.1 +/- 0.04.min-1, respectively.",Pharmacokinetics of sufentanil in patients undergoing renal transplantation. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2968186/),1/[min],0.1,1234,DB00708,Sufentanil
,9512844,gamma,"The parameters gamma, IC50 and t1/2Keo for ASSR were (mean +/- SD) 6.0 +/- 3.7, 2.1 +/- 1.2 ng.",40 Hz auditory steady-state response and EEG spectral edge frequency during sufentanil anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9512844/),ng,6.0,1964,DB00708,Sufentanil
,9512844,IC50,"The parameters gamma, IC50 and t1/2Keo for ASSR were (mean +/- SD) 6.0 +/- 3.7, 2.1 +/- 1.2 ng.",40 Hz auditory steady-state response and EEG spectral edge frequency during sufentanil anaesthesia. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9512844/),ng,2.1,1965,DB00708,Sufentanil
,9512844,t1/2Keo,"The parameters gamma, IC50 and t1/2Keo for ASSR were (mean +/- SD) 6.0 +/- 3.7, 2.1 +/- 1.2 ng.",40 Hz auditory steady-state response and EEG spectral edge frequency during sufentanil anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9512844/),ng,2.1,1966,DB00708,Sufentanil
,19156973,Vc,"The pharmacokinetics of rocuronium in DMD patients were Vc 63 +/- 14 ml kg(-1), Cl 3.0 +/- 1.0 ml min(-1) kg(-1), half-lives 2.0 +/- 0.6, 20 +/- 10 and 129 +/- 98 min, SE.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),[ml] / [kg],63,4924,DB00708,Sufentanil
,19156973,Cl,"The pharmacokinetics of rocuronium in DMD patients were Vc 63 +/- 14 ml kg(-1), Cl 3.0 +/- 1.0 ml min(-1) kg(-1), half-lives 2.0 +/- 0.6, 20 +/- 10 and 129 +/- 98 min, SE.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),[ml] / [kg·min],3.0,4925,DB00708,Sufentanil
,19156973,half-lives,"The pharmacokinetics of rocuronium in DMD patients were Vc 63 +/- 14 ml kg(-1), Cl 3.0 +/- 1.0 ml min(-1) kg(-1), half-lives 2.0 +/- 0.6, 20 +/- 10 and 129 +/- 98 min, SE.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),min,2.0,4926,DB00708,Sufentanil
,19156973,half-lives,"The pharmacokinetics of rocuronium in DMD patients were Vc 63 +/- 14 ml kg(-1), Cl 3.0 +/- 1.0 ml min(-1) kg(-1), half-lives 2.0 +/- 0.6, 20 +/- 10 and 129 +/- 98 min, SE.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),min,20,4927,DB00708,Sufentanil
,19156973,half-lives,"The pharmacokinetics of rocuronium in DMD patients were Vc 63 +/- 14 ml kg(-1), Cl 3.0 +/- 1.0 ml min(-1) kg(-1), half-lives 2.0 +/- 0.6, 20 +/- 10 and 129 +/- 98 min, SE.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),min,129,4928,DB00708,Sufentanil
,19156973,T(1/2)ke0,"In patients with DMD, the equilibration between the central and effect compartment was significantly slower (T(1/2)ke0: 9.7 +/- 0.3 vs. 1.3 +/- 0.1 min) and the EC(50) was significantly smaller (512 +/- 20 vs.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),min,9.7,4929,DB00708,Sufentanil
,19156973,T(1/2)ke0,"In patients with DMD, the equilibration between the central and effect compartment was significantly slower (T(1/2)ke0: 9.7 +/- 0.3 vs. 1.3 +/- 0.1 min) and the EC(50) was significantly smaller (512 +/- 20 vs.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),min,1.3,4930,DB00708,Sufentanil
,19156973,EC(50),"In patients with DMD, the equilibration between the central and effect compartment was significantly slower (T(1/2)ke0: 9.7 +/- 0.3 vs. 1.3 +/- 0.1 min) and the EC(50) was significantly smaller (512 +/- 20 vs.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),,512,4931,DB00708,Sufentanil
,19156973,ED(50),"1170 +/- 64 ng ml(-1)), whereas the ED(50) was 0.16 +/- 0.02 mg kg(-1) in both groups.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),[mg] / [kg],0.16,4932,DB00708,Sufentanil
,15581380,half-time,"By virtue of these distinctive pharmacokinetic properties, the context-sensitive half-time (i.e. the time required for the drug's plasma concentration to decrease by 50% after cessation of an infusion) of remifentanil remains consistently short (3.2 minutes), even following an infusion of long duration (> or =8 hours).",Remifentanil update: clinical science and utility. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15581380/),min,3.2,6722,DB00708,Sufentanil
,9856717,V1,"Typical pharmacokinetic parameters were V1 = 32.2 l, V2 = 53 l, V3 = 245 l, Cl1 = 0.43 l/min, Cl2 = 0.56 l/min, and Cl3 = 0.39 l/min.",Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9856717/),l,32.2,9781,DB00708,Sufentanil
,9856717,V2,"Typical pharmacokinetic parameters were V1 = 32.2 l, V2 = 53 l, V3 = 245 l, Cl1 = 0.43 l/min, Cl2 = 0.56 l/min, and Cl3 = 0.39 l/min.",Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9856717/),l,53,9782,DB00708,Sufentanil
,9856717,V3,"Typical pharmacokinetic parameters were V1 = 32.2 l, V2 = 53 l, V3 = 245 l, Cl1 = 0.43 l/min, Cl2 = 0.56 l/min, and Cl3 = 0.39 l/min.",Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9856717/),l,245,9783,DB00708,Sufentanil
,9856717,Cl1,"Typical pharmacokinetic parameters were V1 = 32.2 l, V2 = 53 l, V3 = 245 l, Cl1 = 0.43 l/min, Cl2 = 0.56 l/min, and Cl3 = 0.39 l/min.",Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9856717/),[l] / [min],0.43,9784,DB00708,Sufentanil
,9856717,Cl2,"Typical pharmacokinetic parameters were V1 = 32.2 l, V2 = 53 l, V3 = 245 l, Cl1 = 0.43 l/min, Cl2 = 0.56 l/min, and Cl3 = 0.39 l/min.",Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9856717/),[l] / [min],0.56,9785,DB00708,Sufentanil
,9856717,Cl3,"Typical pharmacokinetic parameters were V1 = 32.2 l, V2 = 53 l, V3 = 245 l, Cl1 = 0.43 l/min, Cl2 = 0.56 l/min, and Cl3 = 0.39 l/min.",Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9856717/),[l] / [min],0.39,9786,DB00708,Sufentanil
,9856717,elimination half-life,The calculated elimination half-life was 15 h.,Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9856717/),h,15,9787,DB00708,Sufentanil
,18467078,k1e,"For morphine, hysteresis was best described by an extended-catenary biophase distribution model with different values for k1e and keo of 0.038+/-0.003 and 0.043+/-0.003 min(-1), respectively.",Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),1/[min],0.038,14909,DB00708,Sufentanil
,18467078,keo,"For morphine, hysteresis was best described by an extended-catenary biophase distribution model with different values for k1e and keo of 0.038+/-0.003 and 0.043+/-0.003 min(-1), respectively.",Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),1/[min],0.043,14910,DB00708,Sufentanil
,18467078,k1e,"Between the different opioids, the values of k1e ranged from 0.04 to 0.47 min(-1).",Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),1/[min],0.04 to 0.47,14911,DB00708,Sufentanil
,18467078,EC50,Between opioids significant differences in potency (EC50 range 1.2-451 ng/ml) and intrinsic activity (alpha range 18-109 microV) were observed.,Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),[ng] / [ml],1.2-451,14912,DB00708,Sufentanil
,18467078,alpha,Between opioids significant differences in potency (EC50 range 1.2-451 ng/ml) and intrinsic activity (alpha range 18-109 microV) were observed.,Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18467078/),μv,18-109,14913,DB00708,Sufentanil
,23780500,terminal,"Compared with the results of group 2, the ECC procedure reduced the terminal or gamma half-life from 36.35 ± 6.37 h to 23.25 ± 2.75 h in group 1.",Pharmacokinetic assessment of sufentanil in cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780500/),h,36.35,22004,DB00708,Sufentanil
,23780500,gamma half-life,"Compared with the results of group 2, the ECC procedure reduced the terminal or gamma half-life from 36.35 ± 6.37 h to 23.25 ± 2.75 h in group 1.",Pharmacokinetic assessment of sufentanil in cardiac surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23780500/),h,23.25,22005,DB00708,Sufentanil
,20079167,effect-site concentration,"Sufentanil was administered with a specific TCI system incorporating the population pharmacokinetic data of sufentanil previously reported, using a target effect-site concentration of sufentanil 4 or 6 ng/ml.",Clinical evaluation of target controlled infusion system for sufentanil administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079167/),ng,4,23308,DB00708,Sufentanil
,20079167,TCI duration,Sufentanil TCI duration was 30 minutes.,Clinical evaluation of target controlled infusion system for sufentanil administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079167/),min,30,23309,DB00708,Sufentanil
,20079167,Time to eye opening,Time to eye opening and extubation were (5.6 + or - 1.7) minutes when TCI set to 4 ng/ml and (7.2 + or - 2.3) minutes when set to 6 ng/ml.,Clinical evaluation of target controlled infusion system for sufentanil administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079167/),min,5.6,23310,DB00708,Sufentanil
,20079167,extubation,Time to eye opening and extubation were (5.6 + or - 1.7) minutes when TCI set to 4 ng/ml and (7.2 + or - 2.3) minutes when set to 6 ng/ml.,Clinical evaluation of target controlled infusion system for sufentanil administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20079167/),min,7.2,23311,DB00708,Sufentanil
,9009935,V1,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),l,4.98,28910,DB00708,Sufentanil
,9009935,V2,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),l,9.01,28911,DB00708,Sufentanil
,9009935,V3,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),l,6.54,28912,DB00708,Sufentanil
,9009935,Cl1,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),[l] / [min],2.46,28913,DB00708,Sufentanil
,9009935,Cl2,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),[l] / [min],1.69,28914,DB00708,Sufentanil
,9009935,Cl3,"The parameters for the simple three-compartment pharmacokinetic model were V1 = 4.98 l, V2 = 9.01 l, V3 = 6.54 l, Cl1 = 2.46 l/min, Cl2 = 1.69 l/min, and Cl3 = 0.065 l/min.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),[l] / [min],0.065,28915,DB00708,Sufentanil
,9009935,Ke0,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),1/[min],0.516,28916,DB00708,Sufentanil
,9009935,E0,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),hz,20,28917,DB00708,Sufentanil
,9009935,Emax,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),hz,5.62,28918,DB00708,Sufentanil
,9009935,EC50,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),[ng] / [ml],11.2,28919,DB00708,Sufentanil
,9009935,gamma,"The parameters for the simple sigmoid Emax pharmacodynamic model were Ke0 = 0.516 min-1, E0 = 20 Hz, Emax = 5.62 Hz, EC50 = 11.2 ng/ml, and gamma = 2.51.",Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9009935/),,2.51,28920,DB00708,Sufentanil
,14508328,bioavailability,Release rate estimated in vivo was similar to that measured in vitro; bioavailability did not differ from 100%.,Pharmacokinetics of an implanted osmotic pump delivering sufentanil for the treatment of chronic pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508328/),%,100,29506,DB00708,Sufentanil
,14508328,Absorption half-life,Absorption half-life was 16.2 h.,Pharmacokinetics of an implanted osmotic pump delivering sufentanil for the treatment of chronic pain. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508328/),h,16.2,29507,DB00708,Sufentanil
>,14508328,half-life,The rate at which sufentanil was absorbed from the subcutaneous space (half-life > 16 h) was markedly slower than reported with subcutaneous or intramuscular administration of large volumes of dilute opioids; this slow absorption dampens potential changes in Cp if release rate is perturbed.,Pharmacokinetics of an implanted osmotic pump delivering sufentanil for the treatment of chronic pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14508328/),h,16,29508,DB00708,Sufentanil
,2521279,elimination half life,The average (+/- SD) elimination half life was 3.5 +/- 0.9 hrs in controls and did not differ in cirrhotics: 4.1 +/- 0.6 hrs.,Sufentanil pharmacokinetics in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521279/),h,3.5,29718,DB00708,Sufentanil
,2521279,elimination half life,The average (+/- SD) elimination half life was 3.5 +/- 0.9 hrs in controls and did not differ in cirrhotics: 4.1 +/- 0.6 hrs.,Sufentanil pharmacokinetics in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521279/),h,4.1,29719,DB00708,Sufentanil
,2521279,plasma clearance,The plasma clearance did not differ between the two groups: 11.3 +/- 2.5 ml.min-1.kg-1 in controls and 10.8 +/- 4.6 ml.min-1.kg-1 in cirrhotic patients.,Sufentanil pharmacokinetics in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521279/),[ml] / [kg·min],11.3,29720,DB00708,Sufentanil
,2521279,plasma clearance,The plasma clearance did not differ between the two groups: 11.3 +/- 2.5 ml.min-1.kg-1 in controls and 10.8 +/- 4.6 ml.min-1.kg-1 in cirrhotic patients.,Sufentanil pharmacokinetics in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521279/),[ml] / [kg·min],10.8,29721,DB00708,Sufentanil
,2521279,free fraction,The sufentanil free fraction was also similar in controls (8.3 +/- 1.5%) and in cirrhotic patients (9.6 +/- 1.8%).,Sufentanil pharmacokinetics in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521279/),%,8.3,29722,DB00708,Sufentanil
,2521279,free fraction,The sufentanil free fraction was also similar in controls (8.3 +/- 1.5%) and in cirrhotic patients (9.6 +/- 1.8%).,Sufentanil pharmacokinetics in patients with cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2521279/),%,9.6,29723,DB00708,Sufentanil
,2950809,elimination half-lives,"In infants younger than 10 months (group 1) and children older than 10 months (group 2) who were not surface-cooled, elimination half-lives were similar (mean +/- SD, 53 +/- 15 min vs 55 +/- 10 min) as were clearance values (27.5 +/- 9.3 vs 18.1 +/- 10.7 ml X kg-1 X min-1).",Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950809/),min,53,31781,DB00708,Sufentanil
,2950809,elimination half-lives,"In infants younger than 10 months (group 1) and children older than 10 months (group 2) who were not surface-cooled, elimination half-lives were similar (mean +/- SD, 53 +/- 15 min vs 55 +/- 10 min) as were clearance values (27.5 +/- 9.3 vs 18.1 +/- 10.7 ml X kg-1 X min-1).",Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950809/),min,55,31782,DB00708,Sufentanil
,2950809,clearance,"In infants younger than 10 months (group 1) and children older than 10 months (group 2) who were not surface-cooled, elimination half-lives were similar (mean +/- SD, 53 +/- 15 min vs 55 +/- 10 min) as were clearance values (27.5 +/- 9.3 vs 18.1 +/- 10.7 ml X kg-1 X min-1).",Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950809/),[ml] / [kg·min],27.5,31783,DB00708,Sufentanil
,2950809,clearance,"In infants younger than 10 months (group 1) and children older than 10 months (group 2) who were not surface-cooled, elimination half-lives were similar (mean +/- SD, 53 +/- 15 min vs 55 +/- 10 min) as were clearance values (27.5 +/- 9.3 vs 18.1 +/- 10.7 ml X kg-1 X min-1).",Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950809/),[ml] / [kg·min],18.1,31784,DB00708,Sufentanil
,2950809,volumes of distribution,"However, the volumes of distribution were significantly smaller in group 1 compared with group 2 (1.6 +/- 0.46 vs 3.0 +/- 1.3 L/kg).",Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950809/),[l] / [kg],1.6,31785,DB00708,Sufentanil
,2950809,volumes of distribution,"However, the volumes of distribution were significantly smaller in group 1 compared with group 2 (1.6 +/- 0.46 vs 3.0 +/- 1.3 L/kg).",Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950809/),[l] / [kg],3.0,31786,DB00708,Sufentanil
,2950809,elimination half-life,"In infants younger than 10 months who were surface-cooled (group 3) elimination half-life was longer (120 +/- 36 min) and volume of distribution larger (3.7 +/- 1.1 L/kg), but clearance rate was similar (21.5 +/- 5.0 ml X kg-1 X min-1) compared with age- and weight-matched infants (group 1).",Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950809/),min,120,31787,DB00708,Sufentanil
,2950809,volume of distribution,"In infants younger than 10 months who were surface-cooled (group 3) elimination half-life was longer (120 +/- 36 min) and volume of distribution larger (3.7 +/- 1.1 L/kg), but clearance rate was similar (21.5 +/- 5.0 ml X kg-1 X min-1) compared with age- and weight-matched infants (group 1).",Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950809/),[l] / [kg],3.7,31788,DB00708,Sufentanil
,2950809,clearance rate,"In infants younger than 10 months who were surface-cooled (group 3) elimination half-life was longer (120 +/- 36 min) and volume of distribution larger (3.7 +/- 1.1 L/kg), but clearance rate was similar (21.5 +/- 5.0 ml X kg-1 X min-1) compared with age- and weight-matched infants (group 1).",Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2950809/),[ml] / [kg·min],21.5,31789,DB00708,Sufentanil
,9029316,limit of detection,"Using 1-ml plasma samples, the estimated limit of detection of fentanyl was 20 pg/ml.",Determination of subnanogram concentrations of fentanyl in plasma by gas chromatography-mass spectrometry: comparison with standard radioimmunoassay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9029316/),[pg] / [ml],20,33732,DB00708,Sufentanil
,9265933,half-life,The equilibration half-life between plasma and effect site concentrations (T1/2 (keo)) was 16.8 min (median; range: 4.4-41.6 min).,Pharmacodynamic modelling of the analgesic effects of piritramide in postoperative patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9265933/),min,16.8,34917,DB00708,Sufentanil
,9265933,T1/2 (keo)),The equilibration half-life between plasma and effect site concentrations (T1/2 (keo)) was 16.8 min (median; range: 4.4-41.6 min).,Pharmacodynamic modelling of the analgesic effects of piritramide in postoperative patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9265933/),min,16.8,34918,DB00708,Sufentanil
,9265933,steady-state plasma concentration,The steady-state plasma concentration required to produce 50% of maximum analgesia (EC50) was 12.1 ng/ml (range: 2.9-29.8 ng/ml) and correlated with initial pain intensity.,Pharmacodynamic modelling of the analgesic effects of piritramide in postoperative patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9265933/),[ng] / [ml],12.1,34919,DB00708,Sufentanil
,26288466,t peaks,The mean t peaks were measured as 44 ± 22 s and 227 ± 91 s by heart rate and by mean blood pressure respectively.,Estimation of the plasma effect site equilibration rate constant of sufentanil in children using the time to peak effect of heart rate and blood pressure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26288466/),s,44,35512,DB00708,Sufentanil
,26288466,t peaks,The mean t peaks were measured as 44 ± 22 s and 227 ± 91 s by heart rate and by mean blood pressure respectively.,Estimation of the plasma effect site equilibration rate constant of sufentanil in children using the time to peak effect of heart rate and blood pressure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26288466/),s,227,35513,DB00708,Sufentanil
,26288466,ke0,The estimated ke0 were 5.16/min and 0.49/min by heart rate and blood pressure respectively.,Estimation of the plasma effect site equilibration rate constant of sufentanil in children using the time to peak effect of heart rate and blood pressure. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26288466/),1/[min],5.16,35514,DB00708,Sufentanil
,26288466,ke0,The estimated ke0 were 5.16/min and 0.49/min by heart rate and blood pressure respectively.,Estimation of the plasma effect site equilibration rate constant of sufentanil in children using the time to peak effect of heart rate and blood pressure. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26288466/),1/[min],0.49,35515,DB00708,Sufentanil
,6131992,terminal elimination half-life,The terminal elimination half-life was 88 min for alfentanil and 140 min for sufentanil.,Radioimmunoassay of the new opiate analgesics alfentanil and sufentanil. Preliminary pharmacokinetic profile in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6131992/),min,88,39734,DB00708,Sufentanil
,6131992,terminal elimination half-life,The terminal elimination half-life was 88 min for alfentanil and 140 min for sufentanil.,Radioimmunoassay of the new opiate analgesics alfentanil and sufentanil. Preliminary pharmacokinetic profile in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6131992/),min,140,39735,DB00708,Sufentanil
,6131992,plasma,"Six hours after a therapeutic dose, plasma levels were in the order of 3 and 0.3 ng ml-1 for alfentanil and sufentanil respectively.",Radioimmunoassay of the new opiate analgesics alfentanil and sufentanil. Preliminary pharmacokinetic profile in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6131992/),ng,0.3,39736,DB00708,Sufentanil
,8424509,maximum concentration (Cmax),"Sufentanil appeared rapidly in lumbar CSF, reaching a maximum concentration (Cmax) of 57 ng/mL at 6.5 min.",Redistribution of sufentanil to cerebrospinal fluid and systemic circulation after epidural administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424509/),[ng] / [ml],57,44567,DB00708,Sufentanil
,8424509,Cmax,"In cisternal CSF, a Cmax of 1.2 ng/mL was reached at 21 min, and Cmax in plasma was 0.35 ng/mL at 6 min.",Redistribution of sufentanil to cerebrospinal fluid and systemic circulation after epidural administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424509/),[ng] / [ml],1.2,44568,DB00708,Sufentanil
,8424509,Cmax,"In cisternal CSF, a Cmax of 1.2 ng/mL was reached at 21 min, and Cmax in plasma was 0.35 ng/mL at 6 min.",Redistribution of sufentanil to cerebrospinal fluid and systemic circulation after epidural administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424509/),[ng] / [ml],0.35,44569,DB00708,Sufentanil
,9049575,clearance,"Non-compartmental analyses indicated that there was no significant difference in the values of clearance (11.6, 13.3, 14.3 ml.min-1.kg-1), steady-state volume of distribution (0.220, 0.255 and 0.331 l.kg-1) and mean residence time (18.8, 13.3 and 14.3 min) among the groups.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),[ml] / [kg·min],11.6,45783,DB00708,Sufentanil
,9049575,clearance,"Non-compartmental analyses indicated that there was no significant difference in the values of clearance (11.6, 13.3, 14.3 ml.min-1.kg-1), steady-state volume of distribution (0.220, 0.255 and 0.331 l.kg-1) and mean residence time (18.8, 13.3 and 14.3 min) among the groups.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),[ml] / [kg·min],13.3,45784,DB00708,Sufentanil
,9049575,clearance,"Non-compartmental analyses indicated that there was no significant difference in the values of clearance (11.6, 13.3, 14.3 ml.min-1.kg-1), steady-state volume of distribution (0.220, 0.255 and 0.331 l.kg-1) and mean residence time (18.8, 13.3 and 14.3 min) among the groups.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),[ml] / [kg·min],14.3,45785,DB00708,Sufentanil
,9049575,steady-state volume of distribution,"Non-compartmental analyses indicated that there was no significant difference in the values of clearance (11.6, 13.3, 14.3 ml.min-1.kg-1), steady-state volume of distribution (0.220, 0.255 and 0.331 l.kg-1) and mean residence time (18.8, 13.3 and 14.3 min) among the groups.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),[l] / [kg],0.220,45786,DB00708,Sufentanil
,9049575,steady-state volume of distribution,"Non-compartmental analyses indicated that there was no significant difference in the values of clearance (11.6, 13.3, 14.3 ml.min-1.kg-1), steady-state volume of distribution (0.220, 0.255 and 0.331 l.kg-1) and mean residence time (18.8, 13.3 and 14.3 min) among the groups.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),[l] / [kg],0.255,45787,DB00708,Sufentanil
,9049575,steady-state volume of distribution,"Non-compartmental analyses indicated that there was no significant difference in the values of clearance (11.6, 13.3, 14.3 ml.min-1.kg-1), steady-state volume of distribution (0.220, 0.255 and 0.331 l.kg-1) and mean residence time (18.8, 13.3 and 14.3 min) among the groups.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),[l] / [kg],0.331,45788,DB00708,Sufentanil
,9049575,mean residence time,"Non-compartmental analyses indicated that there was no significant difference in the values of clearance (11.6, 13.3, 14.3 ml.min-1.kg-1), steady-state volume of distribution (0.220, 0.255 and 0.331 l.kg-1) and mean residence time (18.8, 13.3 and 14.3 min) among the groups.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),min,18.8,45789,DB00708,Sufentanil
,9049575,mean residence time,"Non-compartmental analyses indicated that there was no significant difference in the values of clearance (11.6, 13.3, 14.3 ml.min-1.kg-1), steady-state volume of distribution (0.220, 0.255 and 0.331 l.kg-1) and mean residence time (18.8, 13.3 and 14.3 min) among the groups.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),min,13.3,45790,DB00708,Sufentanil
,9049575,mean residence time,"Non-compartmental analyses indicated that there was no significant difference in the values of clearance (11.6, 13.3, 14.3 ml.min-1.kg-1), steady-state volume of distribution (0.220, 0.255 and 0.331 l.kg-1) and mean residence time (18.8, 13.3 and 14.3 min) among the groups.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),min,14.3,45791,DB00708,Sufentanil
,9049575,Cmax,"The observed mean Cmax values of 421 (group I), 125 (group II), and 53 (group III) ng.ml-1 and observed mean AUC values from 0 to 3 min were all consistent with the dosing regimens.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),[ng] / [ml],421,45792,DB00708,Sufentanil
,9049575,Cmax,"The observed mean Cmax values of 421 (group I), 125 (group II), and 53 (group III) ng.ml-1 and observed mean AUC values from 0 to 3 min were all consistent with the dosing regimens.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),[ng] / [ml],125,45793,DB00708,Sufentanil
,9049575,Cmax,"The observed mean Cmax values of 421 (group I), 125 (group II), and 53 (group III) ng.ml-1 and observed mean AUC values from 0 to 3 min were all consistent with the dosing regimens.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),[ng] / [ml],53,45794,DB00708,Sufentanil
,9049575,AUC,"The observed mean Cmax values of 421 (group I), 125 (group II), and 53 (group III) ng.ml-1 and observed mean AUC values from 0 to 3 min were all consistent with the dosing regimens.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),min,0 to 3,45795,DB00708,Sufentanil
,9049575,Times to reach peak haemodynamic effect,"Times to reach peak haemodynamic effect ranged from 4.3 to 4.9 min for group I, from 4.6 to 6.1 min for group II, and from 9.9 to 11.3 for group III.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),min,4.3 to 4.9,45796,DB00708,Sufentanil
,9049575,Times to reach peak haemodynamic effect,"Times to reach peak haemodynamic effect ranged from 4.3 to 4.9 min for group I, from 4.6 to 6.1 min for group II, and from 9.9 to 11.3 for group III.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),min,4.6 to 6.1,45797,DB00708,Sufentanil
,9049575,Times to reach peak haemodynamic effect,"Times to reach peak haemodynamic effect ranged from 4.3 to 4.9 min for group I, from 4.6 to 6.1 min for group II, and from 9.9 to 11.3 for group III.",Cardiovascular effects of different infusion rates of sufentanil in patients undergoing coronary surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049575/),,9.9 to 11.3,45798,DB00708,Sufentanil
,24824135,MRT,"Elimination of sufentanil following epidural administration was very slow, with MRT = 28.25 [18.36-44.75] h and t1/2 MRT = 19.57 [12.72-31.01] h.",Pharmacokinetics of sufentanil administered with 0.2% ropivacaine as a continuous epidural infusion for postoperative pain relief in infants. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24824135/),h,28.25,47575,DB00708,Sufentanil
,24824135,t1/2 MRT,"Elimination of sufentanil following epidural administration was very slow, with MRT = 28.25 [18.36-44.75] h and t1/2 MRT = 19.57 [12.72-31.01] h.",Pharmacokinetics of sufentanil administered with 0.2% ropivacaine as a continuous epidural infusion for postoperative pain relief in infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24824135/),h,19.57,47576,DB00708,Sufentanil
,2147593,initial volume of distribution,The initial volume of distribution was significantly smaller in the elderly patients (310 +/- 109 ml.kg-1 vs 491 +/- 112 ml.kg-1 mean +/- SD).,Pharmacokinetics of sufentanil in the elderly surgical patient. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2147593/),[ml] / [kg],310,49463,DB00708,Sufentanil
,2147593,initial volume of distribution,The initial volume of distribution was significantly smaller in the elderly patients (310 +/- 109 ml.kg-1 vs 491 +/- 112 ml.kg-1 mean +/- SD).,Pharmacokinetics of sufentanil in the elderly surgical patient. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2147593/),[ml] / [kg],491,49464,DB00708,Sufentanil
greater,2147593,rate of ventilation,Six of seven elderly patients required administration of naloxone at the termination of surgery to achieve an adequate rate of ventilation (greater than eight breaths.min-1) while only one younger patient required antagonism of ventilatory depression.,Pharmacokinetics of sufentanil in the elderly surgical patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2147593/),[breaths] / [min],eight,49465,DB00708,Sufentanil
,9100179,constant rate,"kg-1, 5 min before induction of anesthesia, and infused at a constant rate of 0.5 microgram.",Predictive accuracy of continuous propofol infusions in neurosurgical patients: comparison of pharmacokinetic models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9100179/),μg,0.5,50314,DB00708,Sufentanil
,15166570,times to recovery,"Mean times to recovery of normal lower urinary tract function were 5 and 8 h after 10 or 30 microg sufentanil and 14 and 20 h after 0.1 or 0.3 mg morphine, respectively.",Intrathecal opioids and lower urinary tract function: a urodynamic evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166570/),h,5,50874,DB00708,Sufentanil
,15166570,times to recovery,"Mean times to recovery of normal lower urinary tract function were 5 and 8 h after 10 or 30 microg sufentanil and 14 and 20 h after 0.1 or 0.3 mg morphine, respectively.",Intrathecal opioids and lower urinary tract function: a urodynamic evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166570/),h,8,50875,DB00708,Sufentanil
,15166570,times to recovery,"Mean times to recovery of normal lower urinary tract function were 5 and 8 h after 10 or 30 microg sufentanil and 14 and 20 h after 0.1 or 0.3 mg morphine, respectively.",Intrathecal opioids and lower urinary tract function: a urodynamic evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166570/),h,14,50876,DB00708,Sufentanil
,15166570,times to recovery,"Mean times to recovery of normal lower urinary tract function were 5 and 8 h after 10 or 30 microg sufentanil and 14 and 20 h after 0.1 or 0.3 mg morphine, respectively.",Intrathecal opioids and lower urinary tract function: a urodynamic evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15166570/),h,20,50877,DB00708,Sufentanil
,2522289,Total drug clearance,Total drug clearance was 15.0 +/- 3.2 ml.min-1.kg-1.,Pharmacokinetics of sufentanil in patients undergoing abdominal aortic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2522289/),[ml] / [kg·min],15.0,52484,DB00708,Sufentanil
,2522289,volume of distribution at steady-state (Vdss),The volume of distribution at steady-state (Vdss) was 8.7 +/- 4.5 l.kg-1.,Pharmacokinetics of sufentanil in patients undergoing abdominal aortic surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2522289/),[l] / [kg],8.7,52485,DB00708,Sufentanil
,2522289,elimination half-time,"In general surgical patients, the mean elimination half-time of sufentanil has been reported to be 2.7 h.",Pharmacokinetics of sufentanil in patients undergoing abdominal aortic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2522289/),h,2.7,52486,DB00708,Sufentanil
,11064622,Maximal median concentrations of plasma,Maximal median concentrations of plasma (0.117-0.247 ng ml-1 for fentanyl and 0.027-0.074 ng ml-1 for sufentanil) were reached approximately 30 and 20 min respectively after the loading doses.,Fentanyl versus sufentanil: plasma concentrations during continuous epidural postoperative infusion in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11064622/),[ng] / [ml],0.117-0.247,54451,DB00708,Sufentanil
,11064622,Maximal median concentrations of plasma,Maximal median concentrations of plasma (0.117-0.247 ng ml-1 for fentanyl and 0.027-0.074 ng ml-1 for sufentanil) were reached approximately 30 and 20 min respectively after the loading doses.,Fentanyl versus sufentanil: plasma concentrations during continuous epidural postoperative infusion in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11064622/),[ng] / [ml],0.027-0.074,54452,DB00708,Sufentanil
,34077940,central volume of distribution (Vdc),"The median (IQR) central volume of distribution (Vdc) and clearance (CL) for sufentanil were 4.7 (4.1-5.4) L/kg and 0.651 (0.433-0.751) L/h/kg, respectively.",Sufentanil Disposition and Pharmacokinetic Model-Based Dosage Regimen for Sufentanil in Ventilated Full-Term Neonates. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34077940/),[l] / [kg],4.7,57288,DB00708,Sufentanil
,34077940,clearance (CL),"The median (IQR) central volume of distribution (Vdc) and clearance (CL) for sufentanil were 4.7 (4.1-5.4) L/kg and 0.651 (0.433-0.751) L/h/kg, respectively.",Sufentanil Disposition and Pharmacokinetic Model-Based Dosage Regimen for Sufentanil in Ventilated Full-Term Neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34077940/),[l] / [h·kg],0.651,57289,DB00708,Sufentanil
,34077940,LD,"Median optimal sufentanil LD and MD were 2.13 (95% CI: 1.78-2.48) μg/kg and 0.29 (95% CI: 0.22-0.37) μg/kg/h, respectively.",Sufentanil Disposition and Pharmacokinetic Model-Based Dosage Regimen for Sufentanil in Ventilated Full-Term Neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34077940/),[μg] / [kg],2.13,57290,DB00708,Sufentanil
,34077940,MD,"Median optimal sufentanil LD and MD were 2.13 (95% CI: 1.78-2.48) μg/kg and 0.29 (95% CI: 0.22-0.37) μg/kg/h, respectively.",Sufentanil Disposition and Pharmacokinetic Model-Based Dosage Regimen for Sufentanil in Ventilated Full-Term Neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34077940/),[μg] / [h·kg],0.29,57291,DB00708,Sufentanil
,1531117,distribution half-life (t1/2 alpha),The distribution half-life (t1/2 alpha) was 5.2 +/- 2.2 (mean +/- SD) min and the elimination half life (t1/2 beta) was 97.0 +/- 42.0 min.,Pharmacokinetics of sufentanil in normal children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531117/),min,5.2,57616,DB00708,Sufentanil
,1531117,elimination half life (t1/2 beta),The distribution half-life (t1/2 alpha) was 5.2 +/- 2.2 (mean +/- SD) min and the elimination half life (t1/2 beta) was 97.0 +/- 42.0 min.,Pharmacokinetics of sufentanil in normal children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531117/),min,97.0,57617,DB00708,Sufentanil
,1531117,volume of distribution at steady state (Vdss),The volume of distribution at steady state (Vdss) was 2.9 +/- 0.6 L.kg-1 and the clearance was 30.5 +/- 8.8 ml.kg-1.min-1.,Pharmacokinetics of sufentanil in normal children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531117/),[l] / [kg],2.9,57618,DB00708,Sufentanil
,1531117,clearance,The volume of distribution at steady state (Vdss) was 2.9 +/- 0.6 L.kg-1 and the clearance was 30.5 +/- 8.8 ml.kg-1.min-1.,Pharmacokinetics of sufentanil in normal children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1531117/),[ml] / [kg·min],30.5,57619,DB00708,Sufentanil
,1844212,plasma clearance,The plasma clearance of sufentanil and fentanyl (902 vs 914 ml.min-1) are similar.,[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[ml] / [min],902,58068,DB00708,Sufentanil
,1844212,plasma clearance,The plasma clearance of sufentanil and fentanyl (902 vs 914 ml.min-1) are similar.,[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[ml] / [min],914,58069,DB00708,Sufentanil
,1844212,volumes of distribution,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[l] / [kg],4.9,58070,DB00708,Sufentanil
,1844212,volumes of distribution,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),[l] / [kg],11.3,58071,DB00708,Sufentanil
,1844212,half-life,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),min,250,58072,DB00708,Sufentanil
,1844212,half-life,"The volumes of distribution are respectively 4.9 and 11.3 l.kg-1, and the half-life 250 and 562 min.",[Clinical and pharmacokinetic comparative study of sufentanil and fentanyl in supratentorial neurosurgery]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1844212/),min,562,58073,DB00708,Sufentanil
,7833228,"t1/2,z","Median (range) values of pharmacokinetic parameters for sufentanil were: t1/2,z = 16 (7-49) h; CL = 1215 (519-2550) ml min-1; CLR = 7 (2-38) ml min-1; Vss = 10.0 (6.8-24.2) 1 kg-1.",Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833228/),h,16,62961,DB00708,Sufentanil
,7833228,CL,"Median (range) values of pharmacokinetic parameters for sufentanil were: t1/2,z = 16 (7-49) h; CL = 1215 (519-2550) ml min-1; CLR = 7 (2-38) ml min-1; Vss = 10.0 (6.8-24.2) 1 kg-1.",Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833228/),[ml] / [min],1215,62962,DB00708,Sufentanil
,7833228,CLR,"Median (range) values of pharmacokinetic parameters for sufentanil were: t1/2,z = 16 (7-49) h; CL = 1215 (519-2550) ml min-1; CLR = 7 (2-38) ml min-1; Vss = 10.0 (6.8-24.2) 1 kg-1.",Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833228/),[ml] / [min],7,62963,DB00708,Sufentanil
,7833228,Vss,"Median (range) values of pharmacokinetic parameters for sufentanil were: t1/2,z = 16 (7-49) h; CL = 1215 (519-2550) ml min-1; CLR = 7 (2-38) ml min-1; Vss = 10.0 (6.8-24.2) 1 kg-1.",Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7833228/),[1] / [kg],10.0,62964,DB00708,Sufentanil
,1671323,CSF/plasma concentration ratio,"No equilibrium was reached between the sufentanil concentration in CSF and plasma, but the CSF/plasma concentration ratio declined from approximately 140 at 2 h to about 15 at 10 h.",The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),,140,63189,DB00708,Sufentanil
,1671323,CSF/plasma concentration ratio,"No equilibrium was reached between the sufentanil concentration in CSF and plasma, but the CSF/plasma concentration ratio declined from approximately 140 at 2 h to about 15 at 10 h.",The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),,15,63190,DB00708,Sufentanil
,1671323,mean residence time (MRT),The mean residence time (MRT) of sufentanil in CSF was 0.92 +/- 0.08 h and in plasma was 6.8 +/- 0.6 h.,The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),h,0.92,63191,DB00708,Sufentanil
,1671323,mean residence time (MRT),The mean residence time (MRT) of sufentanil in CSF was 0.92 +/- 0.08 h and in plasma was 6.8 +/- 0.6 h.,The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),h,6.8,63192,DB00708,Sufentanil
,1671323,volume of distribution at steady state (Vss),"The volume of distribution at steady state (Vss) in the subarachnoid compartment was 1.54 +/- 0.39 ml/kg, and the clearance from the CSF was 27 +/- 5 microliters.",The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),[ml] / [kg],1.54,63193,DB00708,Sufentanil
,1671323,clearance from the CSF,"The volume of distribution at steady state (Vss) in the subarachnoid compartment was 1.54 +/- 0.39 ml/kg, and the clearance from the CSF was 27 +/- 5 microliters.",The CSF and plasma pharmacokinetics of sufentanil after intrathecal administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1671323/),μl,27,63194,DB00708,Sufentanil
,2569886,elimination half-life (T1/2 beta),"There were no differences (based on MI results) between the two groups for elimination half-life (T1/2 beta) (renal failure: 188 min; anaesthetized controls: 195 min), clearance (CI) (1030 and 1093 ml min-1) and apparent volume of distribution at steady state (Vss) (223.0 and 215.3 litre).",Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),min,188,65475,DB00708,Sufentanil
,2569886,elimination half-life (T1/2 beta),"There were no differences (based on MI results) between the two groups for elimination half-life (T1/2 beta) (renal failure: 188 min; anaesthetized controls: 195 min), clearance (CI) (1030 and 1093 ml min-1) and apparent volume of distribution at steady state (Vss) (223.0 and 215.3 litre).",Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),min,195,65476,DB00708,Sufentanil
,2569886,clearance (CI),"There were no differences (based on MI results) between the two groups for elimination half-life (T1/2 beta) (renal failure: 188 min; anaesthetized controls: 195 min), clearance (CI) (1030 and 1093 ml min-1) and apparent volume of distribution at steady state (Vss) (223.0 and 215.3 litre).",Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),[ml] / [min],1030,65477,DB00708,Sufentanil
,2569886,clearance (CI),"There were no differences (based on MI results) between the two groups for elimination half-life (T1/2 beta) (renal failure: 188 min; anaesthetized controls: 195 min), clearance (CI) (1030 and 1093 ml min-1) and apparent volume of distribution at steady state (Vss) (223.0 and 215.3 litre).",Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),[ml] / [min],1093,65478,DB00708,Sufentanil
,2569886,apparent volume of distribution at steady state (Vss),"There were no differences (based on MI results) between the two groups for elimination half-life (T1/2 beta) (renal failure: 188 min; anaesthetized controls: 195 min), clearance (CI) (1030 and 1093 ml min-1) and apparent volume of distribution at steady state (Vss) (223.0 and 215.3 litre).",Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),l,223.0,65479,DB00708,Sufentanil
,2569886,apparent volume of distribution at steady state (Vss),"There were no differences (based on MI results) between the two groups for elimination half-life (T1/2 beta) (renal failure: 188 min; anaesthetized controls: 195 min), clearance (CI) (1030 and 1093 ml min-1) and apparent volume of distribution at steady state (Vss) (223.0 and 215.3 litre).",Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),l,215.3,65480,DB00708,Sufentanil
,2569886,binding to,Sufentanil binding to plasma proteins was 91.4% in the renal patients and 92.2% in the healthy group (ns).,Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),%,91.4,65481,DB00708,Sufentanil
,2569886,binding to,Sufentanil binding to plasma proteins was 91.4% in the renal patients and 92.2% in the healthy group (ns).,Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),%,92.2,65482,DB00708,Sufentanil
,2569886,T1/2 beta,"The mean absolute differences between methods were: T1/2 beta 2.7 min (95% limits: -26.2 to 31.5), CI 36.5 ml min-1 (-5.5 to 78.4), Vss -18.4 litre (-47.7 to 10.9).",Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),min,2.7,65483,DB00708,Sufentanil
,2569886,Vss,"The mean absolute differences between methods were: T1/2 beta 2.7 min (95% limits: -26.2 to 31.5), CI 36.5 ml min-1 (-5.5 to 78.4), Vss -18.4 litre (-47.7 to 10.9).",Sufentanil disposition in patients undergoing renal transplantation: influence of choice of kinetic model. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569886/),l,18.4,65484,DB00708,Sufentanil
,2878076,duration of action,"Alftentanil reaches its peak effect within 1 min after injection, and its duration of action is very short; at 2 times its MED50, 9r has a duration of action of 11 min.","Synthetic 1,4-disubstituted-1,4-dihydro-5H-tetrazol-5-one derivatives of fentanyl: alfentanil (R 39209), a potent, extremely short-acting narcotic analgesic. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878076/),min,11,70928,DB00708,Sufentanil
,15891344,plasma concentrations,"The measured plasma concentrations of sufentanil and ketamine were 0.4 +/- 0.2 ng/mL and 2.6 +/- 2.2 mug/mL, respectively, before the increase in concentrations and 0.7 +/- 0.4 ng/mL and 5.5 +/- 3.8 mug/mL after.",Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15891344/),[ng] / [ml],0.4,71665,DB00708,Sufentanil
,15891344,plasma concentrations,"The measured plasma concentrations of sufentanil and ketamine were 0.4 +/- 0.2 ng/mL and 2.6 +/- 2.2 mug/mL, respectively, before the increase in concentrations and 0.7 +/- 0.4 ng/mL and 5.5 +/- 3.8 mug/mL after.",Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15891344/),[μg] / [ml],2.6,71666,DB00708,Sufentanil
,15891344,plasma concentrations,"The measured plasma concentrations of sufentanil and ketamine were 0.4 +/- 0.2 ng/mL and 2.6 +/- 2.2 mug/mL, respectively, before the increase in concentrations and 0.7 +/- 0.4 ng/mL and 5.5 +/- 3.8 mug/mL after.",Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15891344/),[ng] / [ml],0.7,71667,DB00708,Sufentanil
,15891344,plasma concentrations,"The measured plasma concentrations of sufentanil and ketamine were 0.4 +/- 0.2 ng/mL and 2.6 +/- 2.2 mug/mL, respectively, before the increase in concentrations and 0.7 +/- 0.4 ng/mL and 5.5 +/- 3.8 mug/mL after.",Effects of sufentanil or ketamine administered in target-controlled infusion on the cerebral hemodynamics of severely brain-injured patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15891344/),[μg] / [ml],5.5,71668,DB00708,Sufentanil
below,19247757,Total plasma concentrations,Total plasma concentrations of lidocaine remained below 4 microg ml(-1) throughout the study period.,Intranasal lidocaine plus naphazoline nitrate improves surgical conditions and perioperative analgesia in septorhinoplasty surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19247757/),[μg] / [ml],4,71699,DB00708,Sufentanil
,19330248,Time to extubation,"Time to extubation after the end of propofol infusion was greater in the on-pump coronary artery bypass graft group (334 +/- 117 vs. 216 +/- 85 min, p = 0.04).",Effects of cardiopulmonary bypass on propofol pharmacokinetics and bispectral index during coronary surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19330248/),min,334,72893,DB00708,Sufentanil
,19330248,Time to extubation,"Time to extubation after the end of propofol infusion was greater in the on-pump coronary artery bypass graft group (334 +/- 117 vs. 216 +/- 85 min, p = 0.04).",Effects of cardiopulmonary bypass on propofol pharmacokinetics and bispectral index during coronary surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19330248/),min,216,72894,DB00708,Sufentanil
,19330248,biological,"Patients undergoing cardiopulmonary bypass had shorter biological (1.82 +/- 0.5 vs. 3.67 +/- 1.15 h, p < 0.01) and terminal elimination (6.27 +/- 1.29 vs. 10.5h +/- 2.18, p < 0.01) half-life values, as well as higher total plasma clearance (28.36 +/- 11.40 vs.18.29 +/- 7.67 mL/kg/min, p = 0.03), compared to patients in the off-pump coronary artery bypass graft group.",Effects of cardiopulmonary bypass on propofol pharmacokinetics and bispectral index during coronary surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19330248/),h,1.82,72895,DB00708,Sufentanil
,19330248,biological,"Patients undergoing cardiopulmonary bypass had shorter biological (1.82 +/- 0.5 vs. 3.67 +/- 1.15 h, p < 0.01) and terminal elimination (6.27 +/- 1.29 vs. 10.5h +/- 2.18, p < 0.01) half-life values, as well as higher total plasma clearance (28.36 +/- 11.40 vs.18.29 +/- 7.67 mL/kg/min, p = 0.03), compared to patients in the off-pump coronary artery bypass graft group.",Effects of cardiopulmonary bypass on propofol pharmacokinetics and bispectral index during coronary surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19330248/),h,3.67,72896,DB00708,Sufentanil
,19330248,terminal elimination,"Patients undergoing cardiopulmonary bypass had shorter biological (1.82 +/- 0.5 vs. 3.67 +/- 1.15 h, p < 0.01) and terminal elimination (6.27 +/- 1.29 vs. 10.5h +/- 2.18, p < 0.01) half-life values, as well as higher total plasma clearance (28.36 +/- 11.40 vs.18.29 +/- 7.67 mL/kg/min, p = 0.03), compared to patients in the off-pump coronary artery bypass graft group.",Effects of cardiopulmonary bypass on propofol pharmacokinetics and bispectral index during coronary surgery. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19330248/),h,6.27,72897,DB00708,Sufentanil
,19330248,terminal elimination,"Patients undergoing cardiopulmonary bypass had shorter biological (1.82 +/- 0.5 vs. 3.67 +/- 1.15 h, p < 0.01) and terminal elimination (6.27 +/- 1.29 vs. 10.5h +/- 2.18, p < 0.01) half-life values, as well as higher total plasma clearance (28.36 +/- 11.40 vs.18.29 +/- 7.67 mL/kg/min, p = 0.03), compared to patients in the off-pump coronary artery bypass graft group.",Effects of cardiopulmonary bypass on propofol pharmacokinetics and bispectral index during coronary surgery. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19330248/),h,10.5,72898,DB00708,Sufentanil
,19330248,total plasma clearance,"Patients undergoing cardiopulmonary bypass had shorter biological (1.82 +/- 0.5 vs. 3.67 +/- 1.15 h, p < 0.01) and terminal elimination (6.27 +/- 1.29 vs. 10.5h +/- 2.18, p < 0.01) half-life values, as well as higher total plasma clearance (28.36 +/- 11.40 vs.18.29 +/- 7.67 mL/kg/min, p = 0.03), compared to patients in the off-pump coronary artery bypass graft group.",Effects of cardiopulmonary bypass on propofol pharmacokinetics and bispectral index during coronary surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19330248/),[ml] / [kg·min],28.36,72899,DB00708,Sufentanil
,19330248,total plasma clearance,"Patients undergoing cardiopulmonary bypass had shorter biological (1.82 +/- 0.5 vs. 3.67 +/- 1.15 h, p < 0.01) and terminal elimination (6.27 +/- 1.29 vs. 10.5h +/- 2.18, p < 0.01) half-life values, as well as higher total plasma clearance (28.36 +/- 11.40 vs.18.29 +/- 7.67 mL/kg/min, p = 0.03), compared to patients in the off-pump coronary artery bypass graft group.",Effects of cardiopulmonary bypass on propofol pharmacokinetics and bispectral index during coronary surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19330248/),[ml] / [kg·min],18.29,72900,DB00708,Sufentanil
,25544247,bioavailability,"In the route of administration study (n = 25), mean Cmax values were highest with IV administration, and bioavailability values were: SL, 59%; BU, 78%; and PO, 9%.",Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),%,59,74754,DB00708,Sufentanil
,25544247,bioavailability,"In the route of administration study (n = 25), mean Cmax values were highest with IV administration, and bioavailability values were: SL, 59%; BU, 78%; and PO, 9%.",Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),%,78,74755,DB00708,Sufentanil
,25544247,bioavailability,"In the route of administration study (n = 25), mean Cmax values were highest with IV administration, and bioavailability values were: SL, 59%; BU, 78%; and PO, 9%.",Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),%,9,74756,DB00708,Sufentanil
,25544247,plasma half-time,The absorption across the oral mucosa was associated with a median plasma half-time (time from Cmax to 50% of Cmax) that was 25-fold longer (2.5 hours) with SL versus IV administration (0.1 hours).,Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),h,2.5,74757,DB00708,Sufentanil
,25544247,plasma half-time,The absorption across the oral mucosa was associated with a median plasma half-time (time from Cmax to 50% of Cmax) that was 25-fold longer (2.5 hours) with SL versus IV administration (0.1 hours).,Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),h,0.1,74758,DB00708,Sufentanil
,25544247,AUC0-∞,"In the single- and repeated-dose study (n = 38), mean AUC0-∞ was 125.5 h · pg/mL, and Cmax was 35.0 pg/mL, with a median Tmax of 0.8 hours after the administration of a single sufentanil SL tablet.",Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),[h·pg] / [ml],125.5,74759,DB00708,Sufentanil
,25544247,Cmax,"In the single- and repeated-dose study (n = 38), mean AUC0-∞ was 125.5 h · pg/mL, and Cmax was 35.0 pg/mL, with a median Tmax of 0.8 hours after the administration of a single sufentanil SL tablet.",Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),[pg] / [ml],35.0,74760,DB00708,Sufentanil
,25544247,Tmax,"In the single- and repeated-dose study (n = 38), mean AUC0-∞ was 125.5 h · pg/mL, and Cmax was 35.0 pg/mL, with a median Tmax of 0.8 hours after the administration of a single sufentanil SL tablet.",Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),h,0.8,74761,DB00708,Sufentanil
,25544247,plasma half-time,"Median plasma half-time after the 40th dose was not statistically longer than that after a single dose (2.7 vs 2.2 hours, respectively), and the median Tmax was 0.3 hours after the last repeated dose.",Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),h,2.7,74762,DB00708,Sufentanil
,25544247,plasma half-time,"Median plasma half-time after the 40th dose was not statistically longer than that after a single dose (2.7 vs 2.2 hours, respectively), and the median Tmax was 0.3 hours after the last repeated dose.",Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),h,2.2,74763,DB00708,Sufentanil
,25544247,Tmax,"Median plasma half-time after the 40th dose was not statistically longer than that after a single dose (2.7 vs 2.2 hours, respectively), and the median Tmax was 0.3 hours after the last repeated dose.",Pharmacokinetic properties of single- and repeated-dose sufentanil sublingual tablets in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544247/),h,0.3,74764,DB00708,Sufentanil
,14633756,effect-site concentration,"In the sufentanil group, an effect-site concentration of 0.25 ng x ml(-1) was targeted at extubation.","Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),[ng] / [ml],0.25,77731,DB00708,Sufentanil
,14633756,extubation time,The extubation time was similar in the two groups (mean (SD) 13 (6) and 14 (6) min in the sufentanil and remifentanil groups respectively).,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),min,13,77732,DB00708,Sufentanil
,14633756,extubation time,The extubation time was similar in the two groups (mean (SD) 13 (6) and 14 (6) min in the sufentanil and remifentanil groups respectively).,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),min,14,77733,DB00708,Sufentanil
,14633756,time to first analgesic request,The time to first analgesic request in the postanaesthesia care unit was significantly longer in the sufentanil group than in the remifentanil group (55 (64) (range 2-240) vs 11 (7) (1-29) min; P<0.001).,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),min,55,77734,DB00708,Sufentanil
,14633756,time to first analgesic request,The time to first analgesic request in the postanaesthesia care unit was significantly longer in the sufentanil group than in the remifentanil group (55 (64) (range 2-240) vs 11 (7) (1-29) min; P<0.001).,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),min,11,77735,DB00708,Sufentanil
,14633756,effect-site concentration,TCI sufentanil (0.25 ng ml(-1) effect-site concentration at extubation) is more effective than the intraoperative combination of remifentanil TCI infusion with morphine bolus (0.15 mg x kg(-1)) for postoperative pain relief after major abdominal surgery and does not compromise extubation and recovery.,"Influence of peroperative opioid on postoperative pain after major abdominal surgery: sufentanil TCI versus remifentanil TCI. A randomized, controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14633756/),,0.25,77736,DB00708,Sufentanil
,7784724,FiO2,"Anesthesia was induced with propofol (2 mg/kg), sufentanil (0.5 micrograms/kg), and vecuronium (0.08 mg/kg) and continued as total intravenous anesthesia with propofol (8 mg/kg/h) and oxygen in air (FiO2 = 0.33).",The technique of endobronchial lidocaine administration does not influence plasma concentration profiles and pharmacokinetic parameters in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784724/),,0.,78336,DB00708,Sufentanil
,7784724,maximal mean plasma concentrations,Asorption of lidocaine in groups 1-3 resulted in maximal mean plasma concentrations ranging from 0.78 to 0.85 micrograms/ml after 16.9 to 22.4 min.,The technique of endobronchial lidocaine administration does not influence plasma concentration profiles and pharmacokinetic parameters in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784724/),[μg] / [ml],0.78 to 0.85,78337,DB00708,Sufentanil
,8669668,central compartment volume,Optimal pharmacokinetic parameters were: central compartment volume = 6.0 l; second compartment volume = 49.5 l; third compartment volume = 429.3 l; Cl1 (elimination clearance) = 0.68 l/min; Cl2 (distribution clearance) = 1.97 l/min1; and Cl3 (distribution clearance) = 0.70 l/min.,Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),l,6.0,79392,DB00708,Sufentanil
,8669668,second compartment volume,Optimal pharmacokinetic parameters were: central compartment volume = 6.0 l; second compartment volume = 49.5 l; third compartment volume = 429.3 l; Cl1 (elimination clearance) = 0.68 l/min; Cl2 (distribution clearance) = 1.97 l/min1; and Cl3 (distribution clearance) = 0.70 l/min.,Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),l,49.5,79393,DB00708,Sufentanil
,8669668,third compartment volume,Optimal pharmacokinetic parameters were: central compartment volume = 6.0 l; second compartment volume = 49.5 l; third compartment volume = 429.3 l; Cl1 (elimination clearance) = 0.68 l/min; Cl2 (distribution clearance) = 1.97 l/min1; and Cl3 (distribution clearance) = 0.70 l/min.,Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),l,429.3,79394,DB00708,Sufentanil
,8669668,Cl1 (elimination clearance),Optimal pharmacokinetic parameters were: central compartment volume = 6.0 l; second compartment volume = 49.5 l; third compartment volume = 429.3 l; Cl1 (elimination clearance) = 0.68 l/min; Cl2 (distribution clearance) = 1.97 l/min1; and Cl3 (distribution clearance) = 0.70 l/min.,Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),[l] / [min],0.68,79395,DB00708,Sufentanil
,8669668,Cl2 (distribution clearance),Optimal pharmacokinetic parameters were: central compartment volume = 6.0 l; second compartment volume = 49.5 l; third compartment volume = 429.3 l; Cl1 (elimination clearance) = 0.68 l/min; Cl2 (distribution clearance) = 1.97 l/min1; and Cl3 (distribution clearance) = 0.70 l/min.,Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),[l] / [min1],1.97,79396,DB00708,Sufentanil
,8669668,Cl3 (distribution clearance),Optimal pharmacokinetic parameters were: central compartment volume = 6.0 l; second compartment volume = 49.5 l; third compartment volume = 429.3 l; Cl1 (elimination clearance) = 0.68 l/min; Cl2 (distribution clearance) = 1.97 l/min1; and Cl3 (distribution clearance) = 0.70 l/min.,Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),[l] / [min],0.70,79397,DB00708,Sufentanil
,8669668,V1,"The effects of CPB were optimally modeled by step changes in V1 and Cl1 to values of 15.9 and 1.95, respectively, with the institution of CPB.",Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),,15.9,79398,DB00708,Sufentanil
,8669668,Cl1,"The effects of CPB were optimally modeled by step changes in V1 and Cl1 to values of 15.9 and 1.95, respectively, with the institution of CPB.",Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),,1.95,79399,DB00708,Sufentanil
,10235658,distribution half-life,"The plasma concentration time curves were biexponential and the pharmacokinetic parameters obtained were : distribution half-life 37.24+/-6.57 min, elimination half-life 482.69+/-79 min, clearance 1221.97+/-209.42 ml/min, and volume of distribution 736.46+/-71.25 L.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),min,37.24,80580,DB00708,Sufentanil
,10235658,elimination half-life,"The plasma concentration time curves were biexponential and the pharmacokinetic parameters obtained were : distribution half-life 37.24+/-6.57 min, elimination half-life 482.69+/-79 min, clearance 1221.97+/-209.42 ml/min, and volume of distribution 736.46+/-71.25 L.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),min,482.69,80581,DB00708,Sufentanil
,10235658,clearance,"The plasma concentration time curves were biexponential and the pharmacokinetic parameters obtained were : distribution half-life 37.24+/-6.57 min, elimination half-life 482.69+/-79 min, clearance 1221.97+/-209.42 ml/min, and volume of distribution 736.46+/-71.25 L.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),[ml] / [min],1221.97,80582,DB00708,Sufentanil
,10235658,volume of distribution,"The plasma concentration time curves were biexponential and the pharmacokinetic parameters obtained were : distribution half-life 37.24+/-6.57 min, elimination half-life 482.69+/-79 min, clearance 1221.97+/-209.42 ml/min, and volume of distribution 736.46+/-71.25 L.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),l,736.46,80583,DB00708,Sufentanil
,10235658,plasma BN concentration,"The mean +/- SEM plasma BN concentration during CPB was 0.51+/-0.03 ng/ml which was adequate for the maintenance of analgesia and anaesthesia, as none of our patients expressed the signs and symptoms of awareness during surgery.",Buprenorphine pharmacokinetic parameters during coronary artery bypass graft surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10235658/),[ng] / [ml],0.51,80584,DB00708,Sufentanil
,11942870,steady state plasma concentration,The steady state plasma concentration of ketoprofen was 2.0 microg/mL (range 1.3-2.7 microg/mL).,Pharmacokinetics of a 24-hour intravenous ketoprofen infusion in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11942870/),[μg] / [ml],2.0,80847,DB00708,Sufentanil
,11942870,clearance,The clearance of ketoprofen was 0.09 L x h(-1) x kg(-1) (range 0.06-0.13 L x h(-1) x kg(-1)).,Pharmacokinetics of a 24-hour intravenous ketoprofen infusion in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11942870/),[l] / [h·kg],0.09,80848,DB00708,Sufentanil
,11942870,distribution volume,The distribution volume was 0.16 L/kg (range 0.12-0.21 L/kg).,Pharmacokinetics of a 24-hour intravenous ketoprofen infusion in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11942870/),[l] / [kg],0.16,80849,DB00708,Sufentanil
,11942870,terminal half-life,The terminal half-life was 1.3 h (range 0.8-1.7 h).,Pharmacokinetics of a 24-hour intravenous ketoprofen infusion in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11942870/),h,1.3,80850,DB00708,Sufentanil
,7880508,Plasma concentration,"Plasma concentration of sufentanil at the different time points varied from 0.021 to 0.142 ng/ml, with a mean maximal peak concentration of 0.103 ng/ml.",Investigation of the pharmacokinetics and analgesic effects of an intramuscular injection of sustained-release sufentanil for postoperative pain: an open study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880508/),[ng] / [ml],0.021 to 0.142,82353,DB00708,Sufentanil
,7880508,maximal peak concentration,"Plasma concentration of sufentanil at the different time points varied from 0.021 to 0.142 ng/ml, with a mean maximal peak concentration of 0.103 ng/ml.",Investigation of the pharmacokinetics and analgesic effects of an intramuscular injection of sustained-release sufentanil for postoperative pain: an open study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880508/),[ng] / [ml],0.103,82354,DB00708,Sufentanil
,7880508,plasma concentration,The plasma concentration 48 hours after injection varied from 0.026 to 0.074 ng/ml.,Investigation of the pharmacokinetics and analgesic effects of an intramuscular injection of sustained-release sufentanil for postoperative pain: an open study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880508/),[ng] / [ml],0.026 to 0.074,82355,DB00708,Sufentanil
,29178007,B max,"Analyses of the pooled individual patients' data revealed that clearance maturation relating to body weight could be best described by the Hill function for sufentanil (R 2 = 0.71, B max 876 mL/min, K 50 16.3 kg) and alfentanil (R 2 = 0.70, B max (fixed) 420 mL/min, K 50 28 kg).",Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178007/),[ml] / [min],876,83299,DB00708,Sufentanil
,29178007,B max,"Analyses of the pooled individual patients' data revealed that clearance maturation relating to body weight could be best described by the Hill function for sufentanil (R 2 = 0.71, B max 876 mL/min, K 50 16.3 kg) and alfentanil (R 2 = 0.70, B max (fixed) 420 mL/min, K 50 28 kg).",Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29178007/),[ml] / [min],420,83300,DB00708,Sufentanil
,8533912,central volume of distribution,"The pharmacokinetics of sufentanil were adequately described by a linear three-compartmental mamillary model with the following parameters, expressed as log mean values with 95% confidence intervals: the central volume of distribution = 14.3 l (13.1-15.41), the rapidly equilibrating volume = 63.1 l (61.9-64.3 l), the slowly equilibrating volume = 261.6 l (260.2-262.9 l), the steady-state distribution volume = 339 l (335-343 l), metabolic clearance = 0.92 l.min-1 (0.84-1.05 l.min-1), rapid distribution clearance = 1.55 l.min-1 (1.34-2.14 l.min-1), slow distribution clearance = 0.33 l.min-1 (0.27-0.49 l.min-1), and elimination half-life = 769 min (690-1011 min).",Linearity of pharmacokinetics and model estimation of sufentanil. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533912/),l,14.3,83996,DB00708,Sufentanil
,8533912,volume,"The pharmacokinetics of sufentanil were adequately described by a linear three-compartmental mamillary model with the following parameters, expressed as log mean values with 95% confidence intervals: the central volume of distribution = 14.3 l (13.1-15.41), the rapidly equilibrating volume = 63.1 l (61.9-64.3 l), the slowly equilibrating volume = 261.6 l (260.2-262.9 l), the steady-state distribution volume = 339 l (335-343 l), metabolic clearance = 0.92 l.min-1 (0.84-1.05 l.min-1), rapid distribution clearance = 1.55 l.min-1 (1.34-2.14 l.min-1), slow distribution clearance = 0.33 l.min-1 (0.27-0.49 l.min-1), and elimination half-life = 769 min (690-1011 min).",Linearity of pharmacokinetics and model estimation of sufentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533912/),l,63.1,83997,DB00708,Sufentanil
,8533912,volume,"The pharmacokinetics of sufentanil were adequately described by a linear three-compartmental mamillary model with the following parameters, expressed as log mean values with 95% confidence intervals: the central volume of distribution = 14.3 l (13.1-15.41), the rapidly equilibrating volume = 63.1 l (61.9-64.3 l), the slowly equilibrating volume = 261.6 l (260.2-262.9 l), the steady-state distribution volume = 339 l (335-343 l), metabolic clearance = 0.92 l.min-1 (0.84-1.05 l.min-1), rapid distribution clearance = 1.55 l.min-1 (1.34-2.14 l.min-1), slow distribution clearance = 0.33 l.min-1 (0.27-0.49 l.min-1), and elimination half-life = 769 min (690-1011 min).",Linearity of pharmacokinetics and model estimation of sufentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533912/),l,261.6,83998,DB00708,Sufentanil
,8533912,steady-state distribution volume,"The pharmacokinetics of sufentanil were adequately described by a linear three-compartmental mamillary model with the following parameters, expressed as log mean values with 95% confidence intervals: the central volume of distribution = 14.3 l (13.1-15.41), the rapidly equilibrating volume = 63.1 l (61.9-64.3 l), the slowly equilibrating volume = 261.6 l (260.2-262.9 l), the steady-state distribution volume = 339 l (335-343 l), metabolic clearance = 0.92 l.min-1 (0.84-1.05 l.min-1), rapid distribution clearance = 1.55 l.min-1 (1.34-2.14 l.min-1), slow distribution clearance = 0.33 l.min-1 (0.27-0.49 l.min-1), and elimination half-life = 769 min (690-1011 min).",Linearity of pharmacokinetics and model estimation of sufentanil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533912/),l,339,83999,DB00708,Sufentanil
,8533912,metabolic clearance,"The pharmacokinetics of sufentanil were adequately described by a linear three-compartmental mamillary model with the following parameters, expressed as log mean values with 95% confidence intervals: the central volume of distribution = 14.3 l (13.1-15.41), the rapidly equilibrating volume = 63.1 l (61.9-64.3 l), the slowly equilibrating volume = 261.6 l (260.2-262.9 l), the steady-state distribution volume = 339 l (335-343 l), metabolic clearance = 0.92 l.min-1 (0.84-1.05 l.min-1), rapid distribution clearance = 1.55 l.min-1 (1.34-2.14 l.min-1), slow distribution clearance = 0.33 l.min-1 (0.27-0.49 l.min-1), and elimination half-life = 769 min (690-1011 min).",Linearity of pharmacokinetics and model estimation of sufentanil. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533912/),[l] / [min],0.92,84000,DB00708,Sufentanil
,8533912,distribution clearance,"The pharmacokinetics of sufentanil were adequately described by a linear three-compartmental mamillary model with the following parameters, expressed as log mean values with 95% confidence intervals: the central volume of distribution = 14.3 l (13.1-15.41), the rapidly equilibrating volume = 63.1 l (61.9-64.3 l), the slowly equilibrating volume = 261.6 l (260.2-262.9 l), the steady-state distribution volume = 339 l (335-343 l), metabolic clearance = 0.92 l.min-1 (0.84-1.05 l.min-1), rapid distribution clearance = 1.55 l.min-1 (1.34-2.14 l.min-1), slow distribution clearance = 0.33 l.min-1 (0.27-0.49 l.min-1), and elimination half-life = 769 min (690-1011 min).",Linearity of pharmacokinetics and model estimation of sufentanil. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533912/),[l] / [min],1.55,84001,DB00708,Sufentanil
,8533912,distribution clearance,"The pharmacokinetics of sufentanil were adequately described by a linear three-compartmental mamillary model with the following parameters, expressed as log mean values with 95% confidence intervals: the central volume of distribution = 14.3 l (13.1-15.41), the rapidly equilibrating volume = 63.1 l (61.9-64.3 l), the slowly equilibrating volume = 261.6 l (260.2-262.9 l), the steady-state distribution volume = 339 l (335-343 l), metabolic clearance = 0.92 l.min-1 (0.84-1.05 l.min-1), rapid distribution clearance = 1.55 l.min-1 (1.34-2.14 l.min-1), slow distribution clearance = 0.33 l.min-1 (0.27-0.49 l.min-1), and elimination half-life = 769 min (690-1011 min).",Linearity of pharmacokinetics and model estimation of sufentanil. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533912/),[l] / [min],0.33,84002,DB00708,Sufentanil
,8533912,elimination half-life,"The pharmacokinetics of sufentanil were adequately described by a linear three-compartmental mamillary model with the following parameters, expressed as log mean values with 95% confidence intervals: the central volume of distribution = 14.3 l (13.1-15.41), the rapidly equilibrating volume = 63.1 l (61.9-64.3 l), the slowly equilibrating volume = 261.6 l (260.2-262.9 l), the steady-state distribution volume = 339 l (335-343 l), metabolic clearance = 0.92 l.min-1 (0.84-1.05 l.min-1), rapid distribution clearance = 1.55 l.min-1 (1.34-2.14 l.min-1), slow distribution clearance = 0.33 l.min-1 (0.27-0.49 l.min-1), and elimination half-life = 769 min (690-1011 min).",Linearity of pharmacokinetics and model estimation of sufentanil. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533912/),min,769,84003,DB00708,Sufentanil
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],5,86024,DB00708,Sufentanil
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],3.5,86025,DB00708,Sufentanil
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],2.5,86026,DB00708,Sufentanil
,2529048,AUC0-120 min,The AUC0-120 min after intranasal dosing was 78 per cent of that after intravenous injection.,Comparison of intravenous and intranasal sufentanil absorption and sedation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529048/),%,78,91638,DB00708,Sufentanil
,28510304,CL1,The typical values of systemic clearance scaled to a 70-kg patient for the 2 subpopulations were CL1 = 52.6 L/h and CL2 = 158 L/h.,Flip-Flop Phenomenon in Epidural Sufentanil Pharmacokinetics: A Population Study in Children and Infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28510304/),[l] / [h],52.6,92457,DB00708,Sufentanil
,28510304,CL2,The typical values of systemic clearance scaled to a 70-kg patient for the 2 subpopulations were CL1 = 52.6 L/h and CL2 = 158 L/h.,Flip-Flop Phenomenon in Epidural Sufentanil Pharmacokinetics: A Population Study in Children and Infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28510304/),[l] / [h],158,92458,DB00708,Sufentanil
,28510304,Hill coefficient,The parameters of the Hill function were 54.9 weeks for the postmenstrual age of 50% clearance maturation and 0.802 for the Hill coefficient.,Flip-Flop Phenomenon in Epidural Sufentanil Pharmacokinetics: A Population Study in Children and Infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28510304/),,0.802,92459,DB00708,Sufentanil
,28510304,Q,"The typical values of distribution clearance and volumes of the central and peripheral compartments for a patient with a weight of 70 kg were Q = 40.5 L/h, VC = 7.63 L, and VT = 473 L, respectively.",Flip-Flop Phenomenon in Epidural Sufentanil Pharmacokinetics: A Population Study in Children and Infants. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28510304/),[l] / [h],40.5,92460,DB00708,Sufentanil
,28510304,VC,"The typical values of distribution clearance and volumes of the central and peripheral compartments for a patient with a weight of 70 kg were Q = 40.5 L/h, VC = 7.63 L, and VT = 473 L, respectively.",Flip-Flop Phenomenon in Epidural Sufentanil Pharmacokinetics: A Population Study in Children and Infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28510304/),l,7.63,92461,DB00708,Sufentanil
,28510304,VT,"The typical values of distribution clearance and volumes of the central and peripheral compartments for a patient with a weight of 70 kg were Q = 40.5 L/h, VC = 7.63 L, and VT = 473 L, respectively.",Flip-Flop Phenomenon in Epidural Sufentanil Pharmacokinetics: A Population Study in Children and Infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28510304/),l,473,92462,DB00708,Sufentanil
,28510304,absorption rate constant,"The value of the absorption rate constant from the epidural space was 0.0459/h, which suggests flip-flop pharmacokinetics of sufentanil after epidural administration.",Flip-Flop Phenomenon in Epidural Sufentanil Pharmacokinetics: A Population Study in Children and Infants. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28510304/),1/[h],0.0459,92463,DB00708,Sufentanil
,23895731,volume of distribution at steady-state,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.06,95847,DB00708,Sufentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.25,95848,DB00708,Sufentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,2.18,95849,DB00708,Sufentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,18.6,95850,DB00708,Sufentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,151,95851,DB00708,Sufentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.10,95852,DB00708,Sufentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.89,95853,DB00708,Sufentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,11.6,95854,DB00708,Sufentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,144,95855,DB00708,Sufentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.06,95856,DB00708,Sufentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.77,95857,DB00708,Sufentanil
,23895731,clearance,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,17.6,95858,DB00708,Sufentanil
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,151,95859,DB00708,Sufentanil
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.10,95860,DB00708,Sufentanil
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.89,95861,DB00708,Sufentanil
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,11.6,95862,DB00708,Sufentanil
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,144,95863,DB00708,Sufentanil
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.06,95864,DB00708,Sufentanil
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,0.77,95865,DB00708,Sufentanil
,23895731,terminal half-life,"The volume of the central compartment and the volume of distribution at steady-state (L/kg) [mean ± SEM (range)], the clearance (mL/min/kg) [harmonic mean ± pseudo-SD (range)], and the terminal half-life (min) [median (range)] were 0.25 ± 0.04 (0.09-0.34), 2.18 ± 0.16 (1.79-2.83), 18.6 ± 5.0 (15-29.8), and 151 (115-211) for fentanyl; 0.10 ± 0.01 (0.07-0.14), 0.89 ± 0.16 (0.68-1.83), 11.6 ± 2.6 (9.2-15.8), and 144 (118-501) for alfentanil; and 0.06 ± 0.01 (0.04-0.10), 0.77 ± 0.07 (0.63-0.99), 17.6 ± 4.3 (13.9-24.3), and 54 (46-76) for sufentanil.","Pharmacokinetics of fentanyl, alfentanil, and sufentanil in isoflurane-anesthetized cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23895731/),min,17.6,95866,DB00708,Sufentanil
,28688027,B max,"Analyses of the pooled individual patients' data revealed that clearance maturation relating to body weight could be best described by the Hill function for sufentanil (R 2 = 0.71, B max 876 mL/min, K 50 16.3 kg) and alfentanil (R 2 = 0.70, B max (fixed) 420 mL/min, K 50 28 kg).",Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28688027/),[ml] / [min],876,99082,DB00708,Sufentanil
,28688027,B max,"Analyses of the pooled individual patients' data revealed that clearance maturation relating to body weight could be best described by the Hill function for sufentanil (R 2 = 0.71, B max 876 mL/min, K 50 16.3 kg) and alfentanil (R 2 = 0.70, B max (fixed) 420 mL/min, K 50 28 kg).",Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28688027/),[ml] / [min],420,99083,DB00708,Sufentanil
,9495871,"EC50,u","For the EEG effect the in vivo potencies based on free drug concentrations (EC50,u) were 4.62 +/- 0.66 ng/ml (A), 0.69 +/- 0.05 ng/ml (F) and 0.29 +/- 0.06 ng/ml (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),[ng] / [ml],4.62,103388,DB00708,Sufentanil
,9495871,"EC50,u","For the EEG effect the in vivo potencies based on free drug concentrations (EC50,u) were 4.62 +/- 0.66 ng/ml (A), 0.69 +/- 0.05 ng/ml (F) and 0.29 +/- 0.06 ng/ml (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),[ng] / [ml],0.69,103389,DB00708,Sufentanil
,9495871,"EC50,u","For the EEG effect the in vivo potencies based on free drug concentrations (EC50,u) were 4.62 +/- 0.66 ng/ml (A), 0.69 +/- 0.05 ng/ml (F) and 0.29 +/- 0.06 ng/ml (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),[ng] / [ml],0.29,103390,DB00708,Sufentanil
,9495871,affinities,"In the receptor binding studies the affinities at the mu-opioid receptor (Kl) were 47.4 +/- 6.6 nM (A), 8.6 +/- 4.1 nM (F) and 2.8 +/- 0.2 nM (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),nM,47.4,103391,DB00708,Sufentanil
,9495871,affinities,"In the receptor binding studies the affinities at the mu-opioid receptor (Kl) were 47.4 +/- 6.6 nM (A), 8.6 +/- 4.1 nM (F) and 2.8 +/- 0.2 nM (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),nM,8.6,103392,DB00708,Sufentanil
,9495871,affinities,"In the receptor binding studies the affinities at the mu-opioid receptor (Kl) were 47.4 +/- 6.6 nM (A), 8.6 +/- 4.1 nM (F) and 2.8 +/- 0.2 nM (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),nM,2.8,103393,DB00708,Sufentanil
,9495871,intrinsic activity (Emax),"The intrinsic activity (Emax) of the three opioids in vivo was similar with values of 111 +/- 10 microV (A), 89 +/- 11 microV (F) and 104 +/- 4 microV (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),μv,111,103394,DB00708,Sufentanil
,9495871,intrinsic activity (Emax),"The intrinsic activity (Emax) of the three opioids in vivo was similar with values of 111 +/- 10 microV (A), 89 +/- 11 microV (F) and 104 +/- 4 microV (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),μv,89,103395,DB00708,Sufentanil
,9495871,intrinsic activity (Emax),"The intrinsic activity (Emax) of the three opioids in vivo was similar with values of 111 +/- 10 microV (A), 89 +/- 11 microV (F) and 104 +/- 4 microV (S).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),μv,104,103396,DB00708,Sufentanil
,9495871,sodium shift,"However, the values of the sodium shift varied between 2.8 (S) and 19.1 (A).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),,2.8,103397,DB00708,Sufentanil
,9495871,sodium shift,"However, the values of the sodium shift varied between 2.8 (S) and 19.1 (A).",Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9495871/),,19.1,103398,DB00708,Sufentanil
,30290794,ED50,The ED50 of hydromorphone in our population was 10.9 μg (95% confidence interval 5.6-16.2 μg).,Determination of ED50 and time to effectiveness for intrathecal hydromorphone in laboring patients using Dixon's up-and-down sequential allocation method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30290794/),μg,10.9,105843,DB00708,Sufentanil
,30290794,time to pain relief,"Amongst patients for whom the dose was effective, the median time to pain relief was 24 min.",Determination of ED50 and time to effectiveness for intrathecal hydromorphone in laboring patients using Dixon's up-and-down sequential allocation method. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30290794/),min,24,105844,DB00708,Sufentanil
,19781381,effect-site concentration,"Anesthesia was induced with propofol, rocuronium and sufentanil administered by TCI lasting for 30 minutes, with target effect-site concentration of sufentanil 4 or 6 ng/ml.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),[ng] / [ml],4,109705,DB00708,Sufentanil
,19781381,effect-site concentration,"Anesthesia was induced with propofol, rocuronium and sufentanil administered by TCI lasting for 30 minutes, with target effect-site concentration of sufentanil 4 or 6 ng/ml.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),[ng] / [ml],6,109706,DB00708,Sufentanil
,19781381,volume of central compartment (V(1)),"The variables were derived as follows: the volume of central compartment (V(1)) was 5.4 L, volume of distribution at steady-state (Vdss) was 222.6 L, metabolic clearance (Cl(1)) was 0.84 L/min and elimination half-life (t(1/2Y)) was 389 minutes.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),l,5.4,109707,DB00708,Sufentanil
,19781381,volume of distribution at steady-state (Vdss),"The variables were derived as follows: the volume of central compartment (V(1)) was 5.4 L, volume of distribution at steady-state (Vdss) was 222.6 L, metabolic clearance (Cl(1)) was 0.84 L/min and elimination half-life (t(1/2Y)) was 389 minutes.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),l,222.6,109708,DB00708,Sufentanil
,19781381,metabolic clearance (Cl(1)),"The variables were derived as follows: the volume of central compartment (V(1)) was 5.4 L, volume of distribution at steady-state (Vdss) was 222.6 L, metabolic clearance (Cl(1)) was 0.84 L/min and elimination half-life (t(1/2Y)) was 389 minutes.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),[l] / [min],0.84,109709,DB00708,Sufentanil
,19781381,elimination half-life (t(1/2Y)),"The variables were derived as follows: the volume of central compartment (V(1)) was 5.4 L, volume of distribution at steady-state (Vdss) was 222.6 L, metabolic clearance (Cl(1)) was 0.84 L/min and elimination half-life (t(1/2Y)) was 389 minutes.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),min,389,109710,DB00708,Sufentanil
,25464106,flow rate,"Separation of analytes was performed with a Hypersil C18 column and a mobile phase with acetonitrile and 0.1% formic acid (60/40, v/v) under isocratic conditions at a flow rate of 280μl/min.","Simultaneous detection of ketamine, lorazepam, midazolam and sufentanil in human serum with liquid chromatography-tandem mass spectrometry for monitoring of analgosedation in critically ill patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25464106/),[μl] / [min],280,112299,DB00708,Sufentanil
,11064610,total doses,"Mean total doses of alfentanil, fentanyl and sufentanil were 443, 45 and 4.4 micrograms kg-1, respectively.","Comparison of alfentanil, fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11064610/),,45,113314,DB00708,Sufentanil
,11064610,total doses,"Mean total doses of alfentanil, fentanyl and sufentanil were 443, 45 and 4.4 micrograms kg-1, respectively.","Comparison of alfentanil, fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11064610/),,4.4,113315,DB00708,Sufentanil
,28444856,time to maximum naloxone concentration (Tmax),"Median time to maximum naloxone concentration (Tmax) was 14.5 (95% CI: 9.0-16.5) min, mean maximum naloxone concentration (Cmax) was 1.09 ± 0.56 ng/ml and mean AUC0-90 min was 37.1 ± 15.0 ng*min/ml.",Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444856/),min,14.5,120716,DB00708,Sufentanil
,28444856,maximum naloxone concentration (Cmax),"Median time to maximum naloxone concentration (Tmax) was 14.5 (95% CI: 9.0-16.5) min, mean maximum naloxone concentration (Cmax) was 1.09 ± 0.56 ng/ml and mean AUC0-90 min was 37.1 ± 15.0 ng*min/ml.",Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444856/),[ng] / [ml],1.09,120717,DB00708,Sufentanil
,28444856,AUC0-90 min,"Median time to maximum naloxone concentration (Tmax) was 14.5 (95% CI: 9.0-16.5) min, mean maximum naloxone concentration (Cmax) was 1.09 ± 0.56 ng/ml and mean AUC0-90 min was 37.1 ± 15.0 ng*min/ml.",Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444856/),[min·ng] / [ml],37.1,120718,DB00708,Sufentanil
,28444856,Elimination half-life,Elimination half-life estimated from the median concentration data was 28.2 min.,Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28444856/),min,28.2,120719,DB00708,Sufentanil
,1990898,peak plasma concentration,Intranasal midazolam achieved its peak plasma concentration of 72.2 +/- 27.3 ng/ml in 10.2 +/- 2 min.,Plasma concentrations of midazolam in children following intranasal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1990898/),[ng] / [ml],72.2,121885,DB00708,Sufentanil
,22831891,plasma concentrations,"Anaesthesia was managed with propofol and TCI of sufentanil, using the Gepts model, targeting plasma concentrations of 0.4 (n=18) or 0.8 ng ml(-1) (n=20).",Changes in total and unbound concentrations of sufentanil during target controlled infusion for cardiac surgery with cardiopulmonary bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831891/),[ng] / [ml],0.4,125739,DB00708,Sufentanil
,22831891,plasma concentrations,"Anaesthesia was managed with propofol and TCI of sufentanil, using the Gepts model, targeting plasma concentrations of 0.4 (n=18) or 0.8 ng ml(-1) (n=20).",Changes in total and unbound concentrations of sufentanil during target controlled infusion for cardiac surgery with cardiopulmonary bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831891/),[ng] / [ml],0.8,125740,DB00708,Sufentanil
,8317748,Tmax,A 1.5 h Tmax was observed.,In vivo iontophoresis of fentanyl and sufentanil in rats: pharmacokinetics and acute antinociceptive effects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8317748/),h,1.5,127181,DB00708,Sufentanil
,8317748,maximal plasma levels,The maximal plasma levels after 1.5 h were 29.3 +/- 14 ng/mL for fentanyl and 29.1 +/- 14 ng/mL for sufentanil.,In vivo iontophoresis of fentanyl and sufentanil in rats: pharmacokinetics and acute antinociceptive effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8317748/),[ng] / [ml],29.3,127182,DB00708,Sufentanil
,8317748,maximal plasma levels,The maximal plasma levels after 1.5 h were 29.3 +/- 14 ng/mL for fentanyl and 29.1 +/- 14 ng/mL for sufentanil.,In vivo iontophoresis of fentanyl and sufentanil in rats: pharmacokinetics and acute antinociceptive effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8317748/),[ng] / [ml],29.1,127183,DB00708,Sufentanil
,8447206,hepatic clearance,"The hepatic clearance of the drug was 0.57 l/min after induction and 0.55 l/min at sternotomy, its hepatic extraction 92% and 91%, respectively.",Hepatic disposition of sufentanil in patients undergoing coronary bypass surgery. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447206/),[l] / [min],0.57,127626,DB00708,Sufentanil
,8447206,hepatic clearance,"The hepatic clearance of the drug was 0.57 l/min after induction and 0.55 l/min at sternotomy, its hepatic extraction 92% and 91%, respectively.",Hepatic disposition of sufentanil in patients undergoing coronary bypass surgery. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447206/),[l] / [min],0.55,127627,DB00708,Sufentanil
,8447206,hepatic extraction,"The hepatic clearance of the drug was 0.57 l/min after induction and 0.55 l/min at sternotomy, its hepatic extraction 92% and 91%, respectively.",Hepatic disposition of sufentanil in patients undergoing coronary bypass surgery. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447206/),%,92,127628,DB00708,Sufentanil
,8447206,hepatic extraction,"The hepatic clearance of the drug was 0.57 l/min after induction and 0.55 l/min at sternotomy, its hepatic extraction 92% and 91%, respectively.",Hepatic disposition of sufentanil in patients undergoing coronary bypass surgery. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447206/),%,91,127629,DB00708,Sufentanil
,12502981,target concentration,The effect-site sufentanil target concentration was initially 0.4 ng/ml but was modified during surgery as a function of blood pressure and heart rate.,Performance of target-controlled sufentanil infusion in obese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12502981/),[ng] / [ml],0.4,137589,DB00708,Sufentanil
,12502981,target concentrations,Applied sufentanil target concentrations ranged from 0.3 to 0.65 ng/ml.,Performance of target-controlled sufentanil infusion in obese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12502981/),[ng] / [ml],0.3 to 0.65,137590,DB00708,Sufentanil
,12502981,plasma sufentanil concentration,The mean +/- SD plasma sufentanil concentration measured during spontaneous ventilation was 0.13 +/- 0.03 ng/ml.,Performance of target-controlled sufentanil infusion in obese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12502981/),[ng] / [ml],0.13,137591,DB00708,Sufentanil
,12502981,Clearance,"Clearance, central volume of distribution, intercompartmental clearance, and peripheral volume of distribution (coefficient of variation) were 1.27 l/min (23%), 37.1 l (20%), 0.87 l/min (44%), and 92.7 l (22%), respectively.",Performance of target-controlled sufentanil infusion in obese patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12502981/),[l] / [min],1.27,137592,DB00708,Sufentanil
,12502981,peripheral volume of distribution,"Clearance, central volume of distribution, intercompartmental clearance, and peripheral volume of distribution (coefficient of variation) were 1.27 l/min (23%), 37.1 l (20%), 0.87 l/min (44%), and 92.7 l (22%), respectively.",Performance of target-controlled sufentanil infusion in obese patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12502981/),l,92.7,137593,DB00708,Sufentanil
,21144689,flow rate,"The mobile phase (MP) consisted of acetonitrile:water (45:55, v/v) under isocratic conditions at a flow rate of 0.2 ml/min.",Rapid UPLC-MS/MS method for the determination of sufentanil in human plasma and its application in target-controlled infusion system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21144689/),[ml] / [min],0.2,141456,DB00708,Sufentanil
>,21144689,m,"Sufentanil and internal-standard (IS) fentanyl were eluted at 1.47 and 1.16 min, respectively, and their responses were optimized at the transitions m/z 387.2>238.0 and m/z 337.2>188.0, respectively.",Rapid UPLC-MS/MS method for the determination of sufentanil in human plasma and its application in target-controlled infusion system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21144689/),,33,141457,DB00708,Sufentanil
,21144689,recovery,"The accuracy and precision of the method were between 96.49% and 100.37% (RSD<9%), and the mean recovery of sufentanil was 84.08 ± 7.29%.",Rapid UPLC-MS/MS method for the determination of sufentanil in human plasma and its application in target-controlled infusion system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21144689/),%,84.08,141458,DB00708,Sufentanil
,23271030,Plasma half-time,Plasma half-time (time from peak plasma concentration to 50% of peak concentration) was 80 to 90 minutes for sublingual sufentanil compared with 15 minutes or less for IV sufentanil.,Pharmacokinetics of sublingual sufentanil tablets and efficacy and safety in the management of postoperative pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23271030/),min,80 to 90,145134,DB00708,Sufentanil
,23271030,Plasma half-time,Plasma half-time (time from peak plasma concentration to 50% of peak concentration) was 80 to 90 minutes for sublingual sufentanil compared with 15 minutes or less for IV sufentanil.,Pharmacokinetics of sublingual sufentanil tablets and efficacy and safety in the management of postoperative pain. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23271030/),min,15,145135,DB00708,Sufentanil
,23271030,time from peak plasma concentration to 50% of peak concentration,Plasma half-time (time from peak plasma concentration to 50% of peak concentration) was 80 to 90 minutes for sublingual sufentanil compared with 15 minutes or less for IV sufentanil.,Pharmacokinetics of sublingual sufentanil tablets and efficacy and safety in the management of postoperative pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23271030/),min,80 to 90,145136,DB00708,Sufentanil
,23271030,time from peak plasma concentration to 50% of peak concentration,Plasma half-time (time from peak plasma concentration to 50% of peak concentration) was 80 to 90 minutes for sublingual sufentanil compared with 15 minutes or less for IV sufentanil.,Pharmacokinetics of sublingual sufentanil tablets and efficacy and safety in the management of postoperative pain. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23271030/),min,15,145137,DB00708,Sufentanil
,9806701,elimination rate constant,The elimination rate constant from the peripheral compartment was fixed to the in vitro rate of degradation of cisatracurium in human plasma (0.0237 min(-1)).,Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),1/[min],0.0237,145684,DB00708,Sufentanil
,9806701,rate of degradation,The elimination rate constant from the peripheral compartment was fixed to the in vitro rate of degradation of cisatracurium in human plasma (0.0237 min(-1)).,Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),1/[min],0.0237,145685,DB00708,Sufentanil
,9806701,terminal half-life,"The mean terminal half-life of cisatracurium was 23.9+/-3.3 min, and its total clearance averaged 3.7+/-0.8 mL x min(-1) x kg(-1).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),min,23.9,145686,DB00708,Sufentanil
,9806701,total clearance,"The mean terminal half-life of cisatracurium was 23.9+/-3.3 min, and its total clearance averaged 3.7+/-0.8 mL x min(-1) x kg(-1).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[ml] / [kg·min],3.7,145687,DB00708,Sufentanil
,9806701,volume of distribution at steady state,"Using this model, the volume of distribution at steady state was significantly increased compared with that obtained when central elimination only was assumed (0.118+/-0.027 vs 0.089+/-0.017 L/kg).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[l] / [kg],0.118,145688,DB00708,Sufentanil
,9806701,volume of distribution at steady state,"Using this model, the volume of distribution at steady state was significantly increased compared with that obtained when central elimination only was assumed (0.118+/-0.027 vs 0.089+/-0.017 L/kg).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[l] / [kg],0.089,145689,DB00708,Sufentanil
,9806701,rate constant,The effect-plasma equilibration rate constant was 0.054+/-0.013 min(-1).,Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),1/[min],0.054,145690,DB00708,Sufentanil
,9806701,50% effective concentration,"The 50% effective concentration (153+/-33 ng/mL) was 56% higher than that reported in patients anesthetized with volatile anesthetics, which suggests that, compared with inhaled anesthetics, a cisatracurium neuromuscular block is less enhanced by propofol.",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[ng] / [ml],153,145691,DB00708,Sufentanil
,21223952,plasma fentanyl,"After grouping according to the genotype of CYP3A4*1G, plasma fentanyl concentration in the *1/*1 variant (wild-type) group (12.8±6.5 ng/ml) was significantly lower than that in the *1/*1G group (16.8±9.0 ng/ml, P<0.01) and the *1G/*1G group (28.1±9.5 ng/ml, P<0.01).",Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21223952/),[ng] / [ml],12.8,147062,DB00708,Sufentanil
,21223952,plasma fentanyl,"After grouping according to the genotype of CYP3A4*1G, plasma fentanyl concentration in the *1/*1 variant (wild-type) group (12.8±6.5 ng/ml) was significantly lower than that in the *1/*1G group (16.8±9.0 ng/ml, P<0.01) and the *1G/*1G group (28.1±9.5 ng/ml, P<0.01).",Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21223952/),[ng] / [ml],16.8,147063,DB00708,Sufentanil
,21223952,plasma fentanyl,"After grouping according to the genotype of CYP3A4*1G, plasma fentanyl concentration in the *1/*1 variant (wild-type) group (12.8±6.5 ng/ml) was significantly lower than that in the *1/*1G group (16.8±9.0 ng/ml, P<0.01) and the *1G/*1G group (28.1±9.5 ng/ml, P<0.01).",Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21223952/),[ng] / [ml],28.1,147064,DB00708,Sufentanil
,21223952,concentration,"After grouping according to the genotype of CYP3A4*1G, plasma fentanyl concentration in the *1/*1 variant (wild-type) group (12.8±6.5 ng/ml) was significantly lower than that in the *1/*1G group (16.8±9.0 ng/ml, P<0.01) and the *1G/*1G group (28.1±9.5 ng/ml, P<0.01).",Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21223952/),[ng] / [ml],12.8,147065,DB00708,Sufentanil
,21223952,concentration,"After grouping according to the genotype of CYP3A4*1G, plasma fentanyl concentration in the *1/*1 variant (wild-type) group (12.8±6.5 ng/ml) was significantly lower than that in the *1/*1G group (16.8±9.0 ng/ml, P<0.01) and the *1G/*1G group (28.1±9.5 ng/ml, P<0.01).",Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21223952/),[ng] / [ml],16.8,147066,DB00708,Sufentanil
,21223952,concentration,"After grouping according to the genotype of CYP3A4*1G, plasma fentanyl concentration in the *1/*1 variant (wild-type) group (12.8±6.5 ng/ml) was significantly lower than that in the *1/*1G group (16.8±9.0 ng/ml, P<0.01) and the *1G/*1G group (28.1±9.5 ng/ml, P<0.01).",Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21223952/),[ng] / [ml],28.1,147067,DB00708,Sufentanil
less,12393357,ventilatory frequency,"Respiratory depression was defined as a ventilatory frequency less than10 breaths min(-1) on two occasions or a peripheral oxygen saturation < or =92%, or administration of naloxone.","Remifentanil compared with sufentanil during extra-corporeal shock wave lithotripsy with spontaneous ventilation: a double-blind, randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12393357/),[breaths] / [min],10,152612,DB00708,Sufentanil
,26105145,VC,"Typical values of the central and peripheral volume of distribution and the metabolic and intercompartmental clearance for a theoretical patient weighing 70 kg were VC = 7.90 l, VT = 481 L, Cl = 5.3 L/h, and Q = 38.3 L/h, respectively.",Pharmacokinetics of sufentanil during long-term infusion in critically ill pediatric patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26105145/),l,7.90,156987,DB00708,Sufentanil
,26105145,VT,"Typical values of the central and peripheral volume of distribution and the metabolic and intercompartmental clearance for a theoretical patient weighing 70 kg were VC = 7.90 l, VT = 481 L, Cl = 5.3 L/h, and Q = 38.3 L/h, respectively.",Pharmacokinetics of sufentanil during long-term infusion in critically ill pediatric patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26105145/),l,481,156988,DB00708,Sufentanil
,26105145,Cl,"Typical values of the central and peripheral volume of distribution and the metabolic and intercompartmental clearance for a theoretical patient weighing 70 kg were VC = 7.90 l, VT = 481 L, Cl = 5.3 L/h, and Q = 38.3 L/h, respectively.",Pharmacokinetics of sufentanil during long-term infusion in critically ill pediatric patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26105145/),[l] / [h],5.3,156989,DB00708,Sufentanil
,26105145,Q,"Typical values of the central and peripheral volume of distribution and the metabolic and intercompartmental clearance for a theoretical patient weighing 70 kg were VC = 7.90 l, VT = 481 L, Cl = 5.3 L/h, and Q = 38.3 L/h, respectively.",Pharmacokinetics of sufentanil during long-term infusion in critically ill pediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26105145/),[l] / [h],38.3,156990,DB00708,Sufentanil
,19236806,effect-site concentration,"Anesthetic induction was carried out with propofol, rocuronium and TCI administered sufentanil aiming for target effect-site concentration of sufentanil 4 or 6 ng/ml.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),[ng] / [ml],4,158541,DB00708,Sufentanil
,19236806,effect-site concentration,"Anesthetic induction was carried out with propofol, rocuronium and TCI administered sufentanil aiming for target effect-site concentration of sufentanil 4 or 6 ng/ml.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),[ng] / [ml],6,158542,DB00708,Sufentanil
,19236806,central volume of distribution (V(1)),"The pharmacokinetics of TCI administered sufentanil were optimally described by a three-compartment model with the following parameters: the central volume of distribution (V(1))=5.4 L, the volume of distribution at steady-state (Vdss)=195.4 L, systemic clearance (Cl(1))=1.10 L/min, and elimination half-life (t(1/2) gamma)=271.8 minutes.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),l,5.4,158543,DB00708,Sufentanil
,19236806,volume of distribution at steady-state (Vdss),"The pharmacokinetics of TCI administered sufentanil were optimally described by a three-compartment model with the following parameters: the central volume of distribution (V(1))=5.4 L, the volume of distribution at steady-state (Vdss)=195.4 L, systemic clearance (Cl(1))=1.10 L/min, and elimination half-life (t(1/2) gamma)=271.8 minutes.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),l,195.4,158544,DB00708,Sufentanil
,19236806,systemic clearance (Cl(1)),"The pharmacokinetics of TCI administered sufentanil were optimally described by a three-compartment model with the following parameters: the central volume of distribution (V(1))=5.4 L, the volume of distribution at steady-state (Vdss)=195.4 L, systemic clearance (Cl(1))=1.10 L/min, and elimination half-life (t(1/2) gamma)=271.8 minutes.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),[l] / [min],1.10,158545,DB00708,Sufentanil
,19236806,elimination half-life (t(1/2) gamma),"The pharmacokinetics of TCI administered sufentanil were optimally described by a three-compartment model with the following parameters: the central volume of distribution (V(1))=5.4 L, the volume of distribution at steady-state (Vdss)=195.4 L, systemic clearance (Cl(1))=1.10 L/min, and elimination half-life (t(1/2) gamma)=271.8 minutes.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),min,271.8,158546,DB00708,Sufentanil
,11748515,effect-site concentrations,"Sufentanil was administered by target-controlled infusion, with target effect-site concentrations ranging from 0.4 to 4.5 ng/mL.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[ng] / [ml],0.4 to 4.5,161310,DB00708,Sufentanil
,11748515,V(1),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,5.7,161311,DB00708,Sufentanil
,11748515,V(2),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,18.1,161312,DB00708,Sufentanil
,11748515,V(3),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,225,161313,DB00708,Sufentanil
,11748515,Cl(1),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],0.69,161314,DB00708,Sufentanil
,11748515,Cl(2),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],3.1,161315,DB00708,Sufentanil
,11748515,Cl(3),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],1.4,161316,DB00708,Sufentanil
,9669003,Systemic temperature,Systemic temperature for patients in the normothermic and hypothermic groups was maintained at 33-36 C and 26-30 C respectively.,Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),c,33-36,161929,DB00708,Sufentanil
,9669003,Systemic temperature,Systemic temperature for patients in the normothermic and hypothermic groups was maintained at 33-36 C and 26-30 C respectively.,Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),c,26-30,161930,DB00708,Sufentanil
,9669003,terminal elimination half-life (t1/2 beta),"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,100.1,161931,DB00708,Sufentanil
,9669003,terminal elimination half-life (t1/2 beta),"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,183.8,161932,DB00708,Sufentanil
,9669003,elimination half-life during the CPB phase (T1/2 CPB,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,114.5,161933,DB00708,Sufentanil
,9669003,elimination half-life during the CPB phase (T1/2 CPB,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,183.8,161934,DB00708,Sufentanil
,9669003,mean residence time,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,108.8,161935,DB00708,Sufentanil
,9669003,mean residence time,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),min,164.8,161936,DB00708,Sufentanil
,9669003,apparent volume of distribution at steady state,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),[l] / [kg],0.20,161937,DB00708,Sufentanil
,9669003,apparent volume of distribution at steady state,"For the normothermic and hypothermic groups, terminal elimination half-life (t1/2 beta) was 100.1 +/- 28 and 183.8 +/- 60 min (P < 0.05) respectively, elimination half-life during the CPB phase (T1/2 CPB) 114.5 +/- 10 and 183.8 +/- 60 min (P < 0.05), mean residence time 108.8 +/- 25 and 164.8 +/- 34 min (P < 0.05) and apparent volume of distribution at steady state 0.20 +/- 0.03 and 0.26 +/- 0.04 L.kg-1 (P < 0.05).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),[l] / [kg],0.26,161938,DB00708,Sufentanil
,9669003,rate of renal clearance,"Compared with the hypothermic group, the normothermic group had a higher rate of renal clearance (1.40 +/- 0.4 vs 0.93 +/- 0.3 ml.min-1.kg-1; P < 0.05) and a higher value for renal clearance as a percentage of the total clearance (76.2 +/- 10 vs 58.3 +/- 20%).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),[ml] / [kg·min],1.40,161939,DB00708,Sufentanil
,9669003,rate of renal clearance,"Compared with the hypothermic group, the normothermic group had a higher rate of renal clearance (1.40 +/- 0.4 vs 0.93 +/- 0.3 ml.min-1.kg-1; P < 0.05) and a higher value for renal clearance as a percentage of the total clearance (76.2 +/- 10 vs 58.3 +/- 20%).",Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9669003/),[ml] / [kg·min],0.93,161940,DB00708,Sufentanil
,7791108,ED50,The ED50 for morphine analgesia in 10-day-old pups was 0.35 mg/kg and increased with age to 5.3 mg/kg on day 27.,Increased sensitivity to mu opiate antinociception in the neonatal rat despite weaker receptor-guanyl nucleotide binding protein coupling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791108/),[mg] / [kg],0.35,163091,DB00708,Sufentanil
,7791108,ED50,The ED50 for morphine analgesia in 10-day-old pups was 0.35 mg/kg and increased with age to 5.3 mg/kg on day 27.,Increased sensitivity to mu opiate antinociception in the neonatal rat despite weaker receptor-guanyl nucleotide binding protein coupling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791108/),,5,163092,DB00708,Sufentanil
,7791108,ED50,"Similarly, sufentanil was more potent in pups than in weanlings, the ED50 increasing from 1.7 to 7.6 micrograms/kg.",Increased sensitivity to mu opiate antinociception in the neonatal rat despite weaker receptor-guanyl nucleotide binding protein coupling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791108/),[μg] / [kg],1.7,163093,DB00708,Sufentanil
,7791108,ED50,"Similarly, sufentanil was more potent in pups than in weanlings, the ED50 increasing from 1.7 to 7.6 micrograms/kg.",Increased sensitivity to mu opiate antinociception in the neonatal rat despite weaker receptor-guanyl nucleotide binding protein coupling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791108/),[μg] / [kg],7.6,163094,DB00708,Sufentanil
,7791108,T1/2,"Serum and brain morphine levels after 5 mg/kg of morphine were higher in neonates (day 10) than weanlings (day 27), largely due to a more rapid redistribution phase in weanlings (T1/2 = 26 min.) than in pups (T1/2 = 2.5 hr).",Increased sensitivity to mu opiate antinociception in the neonatal rat despite weaker receptor-guanyl nucleotide binding protein coupling. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791108/),min,26,163095,DB00708,Sufentanil
,7791108,T1/2,"Serum and brain morphine levels after 5 mg/kg of morphine were higher in neonates (day 10) than weanlings (day 27), largely due to a more rapid redistribution phase in weanlings (T1/2 = 26 min.) than in pups (T1/2 = 2.5 hr).",Increased sensitivity to mu opiate antinociception in the neonatal rat despite weaker receptor-guanyl nucleotide binding protein coupling. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7791108/),h,2.5,163096,DB00708,Sufentanil
,1989741,volume of the central compartment,"The volume of the central compartment and the volume of distribution at steady state (Vdss) were 0.44 +/- 0.022 and 0.63 +/- 0.32 L.kg-1, respectively.",Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989741/),[l] / [kg],0.44,163236,DB00708,Sufentanil
,1989741,volume of distribution at steady state (Vdss),"The volume of the central compartment and the volume of distribution at steady state (Vdss) were 0.44 +/- 0.022 and 0.63 +/- 0.32 L.kg-1, respectively.",Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989741/),[l] / [kg],0.63,163237,DB00708,Sufentanil
,1989741,Total drug clearance,Total drug clearance was 6.4 = 1.9 ml.min-1.kg-1.,Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989741/),[ml] / [kg·min],6.4,163238,DB00708,Sufentanil
,1989741,elimination half-time,The elimination half-time was 3.7 +/- 2.6 hr.,Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989741/),h,3.7,163239,DB00708,Sufentanil
,1989741,elimination half-time,"In general surgical patients, the elimination half-time of alfentanil has been reported to be 1.2-2.0 hr.",Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989741/),h,1.2-2.0,163240,DB00708,Sufentanil
,2573385,total volume of distribution,Calculation of the pharmacokinetic parameters from the derived compartmental models demonstrated an increased total volume of distribution of sufentanil in hypocapnic patients (mean 5427 (SD 1866) ml kg-1 v. 3518 (1097) ml kg-1; P less than 0.05) in the control patients and a more prolonged elimination half-life (232 (60) min v. 143 (51) min; P less than 0.01).,Pharmacokinetics of sufentanil in neurosurgical patients undergoing hyperventilation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573385/),[ml] / [kg],5427,164862,DB00708,Sufentanil
,2573385,total volume of distribution,Calculation of the pharmacokinetic parameters from the derived compartmental models demonstrated an increased total volume of distribution of sufentanil in hypocapnic patients (mean 5427 (SD 1866) ml kg-1 v. 3518 (1097) ml kg-1; P less than 0.05) in the control patients and a more prolonged elimination half-life (232 (60) min v. 143 (51) min; P less than 0.01).,Pharmacokinetics of sufentanil in neurosurgical patients undergoing hyperventilation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573385/),[ml] / [kg],3518,164863,DB00708,Sufentanil
,2573385,elimination half-life,Calculation of the pharmacokinetic parameters from the derived compartmental models demonstrated an increased total volume of distribution of sufentanil in hypocapnic patients (mean 5427 (SD 1866) ml kg-1 v. 3518 (1097) ml kg-1; P less than 0.05) in the control patients and a more prolonged elimination half-life (232 (60) min v. 143 (51) min; P less than 0.01).,Pharmacokinetics of sufentanil in neurosurgical patients undergoing hyperventilation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573385/),min,232,164864,DB00708,Sufentanil
,2573385,elimination half-life,Calculation of the pharmacokinetic parameters from the derived compartmental models demonstrated an increased total volume of distribution of sufentanil in hypocapnic patients (mean 5427 (SD 1866) ml kg-1 v. 3518 (1097) ml kg-1; P less than 0.05) in the control patients and a more prolonged elimination half-life (232 (60) min v. 143 (51) min; P less than 0.01).,Pharmacokinetics of sufentanil in neurosurgical patients undergoing hyperventilation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573385/),min,143,164865,DB00708,Sufentanil
,8694326,elimination half-life,"The elimination half-life in plasma (mean +/- SEM) was 9.9 +/- 1.7 h (Ls), 8.6 +/- 0.7 h (Ts), and 11.7 +/- 2.2 h (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),h,9.9,168144,DB00708,Sufentanil
,8694326,Ts,"The elimination half-life in plasma (mean +/- SEM) was 9.9 +/- 1.7 h (Ls), 8.6 +/- 0.7 h (Ts), and 11.7 +/- 2.2 h (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),h,8.6,168145,DB00708,Sufentanil
,8694326,Tsb,"The elimination half-life in plasma (mean +/- SEM) was 9.9 +/- 1.7 h (Ls), 8.6 +/- 0.7 h (Ts), and 11.7 +/- 2.2 h (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),h,11.7,168146,DB00708,Sufentanil
,8694326,distribution volume,"The distribution volume was 15.2 +/- 3.5 l/kg (Ls), 14.8 +/- 2.4 L/kg (Ts), and 12.9 +/- 1.2 L/kg (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[l] / [kg],15.2,168147,DB00708,Sufentanil
,8694326,distribution volume,"The distribution volume was 15.2 +/- 3.5 l/kg (Ls), 14.8 +/- 2.4 L/kg (Ts), and 12.9 +/- 1.2 L/kg (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[l] / [kg],14.8,168148,DB00708,Sufentanil
,8694326,distribution volume,"The distribution volume was 15.2 +/- 3.5 l/kg (Ls), 14.8 +/- 2.4 L/kg (Ts), and 12.9 +/- 1.2 L/kg (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[l] / [kg],12.9,168149,DB00708,Sufentanil
,8694326,Ts,"The distribution volume was 15.2 +/- 3.5 l/kg (Ls), 14.8 +/- 2.4 L/kg (Ts), and 12.9 +/- 1.2 L/kg (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[l] / [kg],14.8,168150,DB00708,Sufentanil
,8694326,Tsb,"The distribution volume was 15.2 +/- 3.5 l/kg (Ls), 14.8 +/- 2.4 L/kg (Ts), and 12.9 +/- 1.2 L/kg (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[l] / [kg],12.9,168151,DB00708,Sufentanil
,8694326,clearance,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],17.8,168152,DB00708,Sufentanil
,8694326,clearance,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],16.9,168153,DB00708,Sufentanil
,8694326,clearance,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],22.9,168154,DB00708,Sufentanil
,8694326,clearance,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],20.0,168155,DB00708,Sufentanil
,8694326,Ts,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],20.0,168156,DB00708,Sufentanil
,8694326,Tsb,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],22.4,168157,DB00708,Sufentanil
,8694326,Tsb,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],14.5,168158,DB00708,Sufentanil
,8694326,terminal elimination half-life,The terminal elimination half-life of sufentanil in CSF was 7.2 +/- 0.6 h.,The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),h,7.2,168159,DB00708,Sufentanil
,8602663,recovery times to T(1),"In the carbamazepine group, the mean recovery times to T(1) 25% were shorter (28.1 +/- 3.4 vs. 47.3 +/- 5.1 min in control subjects; P=0.007), and the T(1) 25% to T(1) 75% recovery index was decreased (7.6 +/- 1.2 vs. 21.9 +/- 6.8 min in control subjects; P=0.025).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,28.1,180814,DB00708,Sufentanil
,8602663,recovery times to T(1),"In the carbamazepine group, the mean recovery times to T(1) 25% were shorter (28.1 +/- 3.4 vs. 47.3 +/- 5.1 min in control subjects; P=0.007), and the T(1) 25% to T(1) 75% recovery index was decreased (7.6 +/- 1.2 vs. 21.9 +/- 6.8 min in control subjects; P=0.025).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,47.3,180815,DB00708,Sufentanil
,8602663,T(1) 25% to T(1) 75% recovery index,"In the carbamazepine group, the mean recovery times to T(1) 25% were shorter (28.1 +/- 3.4 vs. 47.3 +/- 5.1 min in control subjects; P=0.007), and the T(1) 25% to T(1) 75% recovery index was decreased (7.6 +/- 1.2 vs. 21.9 +/- 6.8 min in control subjects; P=0.025).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,7.6,180816,DB00708,Sufentanil
,8602663,T(1) 25% to T(1) 75% recovery index,"In the carbamazepine group, the mean recovery times to T(1) 25% were shorter (28.1 +/- 3.4 vs. 47.3 +/- 5.1 min in control subjects; P=0.007), and the T(1) 25% to T(1) 75% recovery index was decreased (7.6 +/- 1.2 vs. 21.9 +/- 6.8 min in control subjects; P=0.025).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,21.9,180817,DB00708,Sufentanil
,8602663,Clearance,"Clearance was 9.0 +/- 1.2 ml x kg-1 x min-1 versus 3.8 +/- 0.3 in the control group (P=0.003), whereas no changes in volumes of distribution at steady-state were observed.",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),[ml] / [kg·min],9.0,180818,DB00708,Sufentanil
,8602663,Clearance,"Clearance was 9.0 +/- 1.2 ml x kg-1 x min-1 versus 3.8 +/- 0.3 in the control group (P=0.003), whereas no changes in volumes of distribution at steady-state were observed.",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),,3.8,180819,DB00708,Sufentanil
,8602663,mean residence time,"Therefore, the mean residence time was halved (17.8 +/- 2.5 vs. 31.9 +/- 2.5 min in control subjects; P=0.001).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,17.8,180820,DB00708,Sufentanil
,8602663,mean residence time,"Therefore, the mean residence time was halved (17.8 +/- 2.5 vs. 31.9 +/- 2.5 min in control subjects; P=0.001).",Pharmacokinetic origin of carbamazepine-induced resistance to vecuronium neuromuscular blockade in anesthetized patients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8602663/),min,31.9,180821,DB00708,Sufentanil
,10069275,Total sufen,Total sufentanil dose was 773 +/- 186 microg in the continuous-infusion group and 610 +/- 184 microg in the bolus group (p = 0.01).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),μg,773,186592,DB00708,Sufentanil
,10069275,dose,Total sufentanil dose was 773 +/- 186 microg in the continuous-infusion group and 610 +/- 184 microg in the bolus group (p = 0.01).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),μg,773,186593,DB00708,Sufentanil
,10069275,dose,Total sufentanil dose was 773 +/- 186 microg in the continuous-infusion group and 610 +/- 184 microg in the bolus group (p = 0.01).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),μ,610,186594,DB00708,Sufentanil
,10069275,Total midazolam dose,"Total midazolam dose was 14.4 +/- 3 mg and 11.2 +/- 3 mg in the continuous-infusion and bolus groups, respectively.",Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),mg,14.4,186595,DB00708,Sufentanil
,10069275,Total midazolam dose,"Total midazolam dose was 14.4 +/- 3 mg and 11.2 +/- 3 mg in the continuous-infusion and bolus groups, respectively.",Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),mg,11.2,186596,DB00708,Sufentanil
,10069275,Plasma,Plasma sufentanil concentrations at extubation were similar in both groups (0.5 ng/mL).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),[ng] / [ml],0.5,186597,DB00708,Sufentanil
,10069275,Plasma midazolam concentrations,Plasma midazolam concentrations at extubation in the bolus group (17 +/- 6.7 ng/mL) were similar to those in the continuous-infusion group (23 +/- 5 ng/mL).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),[ng] / [ml],17,186598,DB00708,Sufentanil
,10069275,Plasma midazolam concentrations,Plasma midazolam concentrations at extubation in the bolus group (17 +/- 6.7 ng/mL) were similar to those in the continuous-infusion group (23 +/- 5 ng/mL).,Continuous infusion versus bolus administration of sufentanil and midazolam for mitral valve surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10069275/),[ng] / [ml],23,186599,DB00708,Sufentanil
,29498947,Bioavailability,"Bioavailability of a single sublingual tablet was 52%, decreasing to 35% with repeat dosing.",Pharmacokinetic Properties of a Sufentanil Sublingual Tablet Intended to Treat Acute Pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29498947/),%,52,187661,DB00708,Sufentanil
,29498947,Bioavailability,"Bioavailability of a single sublingual tablet was 52%, decreasing to 35% with repeat dosing.",Pharmacokinetic Properties of a Sufentanil Sublingual Tablet Intended to Treat Acute Pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29498947/),%,35,187662,DB00708,Sufentanil
,29498947,Time for concentrations to decrease 50% from maximal,Time for concentrations to decrease 50% from maximal values was similar after 1 dose (2.5 ± 0.85 h) and 12 doses (2.5 ± 0.72 h).,Pharmacokinetic Properties of a Sufentanil Sublingual Tablet Intended to Treat Acute Pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29498947/),h,2.5,187663,DB00708,Sufentanil
,29498947,Time for concentrations to decrease 50% from maximal,Time for concentrations to decrease 50% from maximal values was similar after 1 dose (2.5 ± 0.85 h) and 12 doses (2.5 ± 0.72 h).,Pharmacokinetic Properties of a Sufentanil Sublingual Tablet Intended to Treat Acute Pain. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29498947/),h,2.5,187664,DB00708,Sufentanil
,2960465,central compartment concentration,"At that point, an infusion of sufentanil, aimed to reach a central compartment concentration of 5 ng.",Sufentanil disposition during cardiopulmonary bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960465/),ng,5,190294,DB00708,Sufentanil
,2960465,Plasma concentrations,Plasma concentrations of sufentanil reached 3.8 +/- 0.4 ng.,Sufentanil disposition during cardiopulmonary bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2960465/),ng,3.8,190295,DB00708,Sufentanil
,10969297,plasma target concentrations,The range of plasma target concentrations was 2-5 microgram/ml for propofol and 0.2-1 ng/ml for sufentanil.,Predictive accuracy of target-controlled propofol and sufentanil coinfusion in long-lasting surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969297/),[μg] / [ml],2-5,192254,DB00708,Sufentanil
,10969297,plasma target concentrations,The range of plasma target concentrations was 2-5 microgram/ml for propofol and 0.2-1 ng/ml for sufentanil.,Predictive accuracy of target-controlled propofol and sufentanil coinfusion in long-lasting surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969297/),[ng] / [ml],0.2-1,192255,DB00708,Sufentanil
,10969297,wobble,"The wobble values were 11.6% and 22.3% for propofol and sufentanil, respectively.",Predictive accuracy of target-controlled propofol and sufentanil coinfusion in long-lasting surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969297/),%,11.6,192256,DB00708,Sufentanil
,10969297,wobble,"The wobble values were 11.6% and 22.3% for propofol and sufentanil, respectively.",Predictive accuracy of target-controlled propofol and sufentanil coinfusion in long-lasting surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969297/),%,22.3,192257,DB00708,Sufentanil
,12923616,duration of sedation,The mean duration of sedation was 12+/-7 days.,Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12923616/),d,12,198213,DB00708,Sufentanil
,12923616,initial half-life t(1/2alpha),The initial half-life t(1/2alpha) was 1.33+/-1.15 h.,Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12923616/),h,1.33,198214,DB00708,Sufentanil
,12923616,elimination half-life (t(1/2beta),The observed prolonged elimination half-life (t(1/2beta)=25.5+/-9.4 h) was related to the large volume of distribution (Vdbeta=22.6+/-9.4 l/kg).,Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12923616/),h,25.5,198215,DB00708,Sufentanil
,12923616,volume of distribution (Vdbeta,The observed prolonged elimination half-life (t(1/2beta)=25.5+/-9.4 h) was related to the large volume of distribution (Vdbeta=22.6+/-9.4 l/kg).,Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12923616/),[l] / [kg],22.6,198216,DB00708,Sufentanil
,12923616,total clearance,The mean total clearance was 13.4+/-7.0 ml/kg per minute.,Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12923616/),[ml] / [kg·min],13.4,198217,DB00708,Sufentanil
,12923616,tcp(0/2,The mean time required to obtain a 50% decrease in plasma concentration was short (tcp(0/2=)4.7+/-3.7 h).,Pharmacokinetics of long-term sufentanil infusion for sedation in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12923616/),h,4.7,198218,DB00708,Sufentanil
,2155718,t1/2,Plasma and urine concentrations of pipecuronium were also measured and the pharmacokinetic variables obtained indicated rapid initial decrease in plasma concentration (t1/2 = 7.6 minutes) followed by a longer terminal phase (t1/2 = 161 minutes).,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),min,7.6,199052,DB00708,Sufentanil
,2155718,terminal phase (t1/2,Plasma and urine concentrations of pipecuronium were also measured and the pharmacokinetic variables obtained indicated rapid initial decrease in plasma concentration (t1/2 = 7.6 minutes) followed by a longer terminal phase (t1/2 = 161 minutes).,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),min,161,199053,DB00708,Sufentanil
,2155718,central compartment volume,The central compartment volume was 102 +/- 24 ml.kg-1 and plasma clearance was 1.8 +/- 0.4 ml.kg-1 min-1.,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),[ml] / [kg],102,199054,DB00708,Sufentanil
,2155718,plasma clearance,The central compartment volume was 102 +/- 24 ml.kg-1 and plasma clearance was 1.8 +/- 0.4 ml.kg-1 min-1.,Pharmacokinetics and cardiovascular dynamics of pipecuronium bromide during coronary artery surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155718/),[ml] / [kg·min],1.8,199055,DB00708,Sufentanil
,15907650,half-lives,Alfentanil and remifentanil are very fast equilibrating opioids with equilibration half-lives between plasma and effect site of about 1 minute.,Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),min,1,199979,DB00708,Sufentanil
,15907650,half-lives,"They are followed by fentanyl and sufentanil, each with equilibration half-lives of about 6 min.",Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),min,6,199980,DB00708,Sufentanil
,15907650,half-life,Methadone equilibrates with a half-life of about 8 min.,Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),min,8,199981,DB00708,Sufentanil
,15907650,half-life,"Morphine, in contrast, equilibrates with a half-life of 2-3 h.",Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),h,2-3,199982,DB00708,Sufentanil
,15907650,half-life,"The slowest opioid with respect to plasma-effect site transfer is M6G, with an equilibration half-life of about 7 h.",Pharmacokinetic-pharmacodynamic modeling of opioids. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15907650/),h,7,199983,DB00708,Sufentanil
,32486875,plasma elimination half-life,Mean plasma elimination half-life is 13 hours and bioavailability 47-57% after the first sublingual sufentanil tablet.,An up-to-date overview of sublingual sufentanil for the treatment of moderate to severe pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486875/),h,13,204667,DB00708,Sufentanil
,32486875,bioavailability,Mean plasma elimination half-life is 13 hours and bioavailability 47-57% after the first sublingual sufentanil tablet.,An up-to-date overview of sublingual sufentanil for the treatment of moderate to severe pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32486875/),%,47-57,204668,DB00708,Sufentanil
,2932983,detection limit,The detection limit for sufentanil and its metabolites is 30-50 pg/ml with minimal interfering substances in the chromatograms.,Detection of picogram levels of sufentanil by capillary gas chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2932983/),[pg] / [ml],30-50,209664,DB00708,Sufentanil
,29494402,cardiac outputs,"The cardiac outputs (means ± SD) were 2.9 ± 0.7, 5.4 ± 0.7, and 9.6 ± 1.6 l/min in the low, control, and high cardiac output groups, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],2.9,213441,DB00708,Sufentanil
,29494402,cardiac outputs,"The cardiac outputs (means ± SD) were 2.9 ± 0.7, 5.4 ± 0.7, and 9.6 ± 1.6 l/min in the low, control, and high cardiac output groups, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],5.4,213442,DB00708,Sufentanil
,29494402,cardiac outputs,"The cardiac outputs (means ± SD) were 2.9 ± 0.7, 5.4 ± 0.7, and 9.6 ± 1.6 l/min in the low, control, and high cardiac output groups, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],9.6,213443,DB00708,Sufentanil
,29494402,CL1,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],0.9,213444,DB00708,Sufentanil
,29494402,CL1,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],1.2,213445,DB00708,Sufentanil
,29494402,CL1,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],1.7,213446,DB00708,Sufentanil
,29494402,CL2,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],0.9,213447,DB00708,Sufentanil
,29494402,CL2,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],3.1,213448,DB00708,Sufentanil
,29494402,CL2,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],6.9,213449,DB00708,Sufentanil
,29494402,V1,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),l,1.6,213450,DB00708,Sufentanil
,29494402,V1,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),l,2.9,213451,DB00708,Sufentanil
,29494402,V1,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),l,5.2,213452,DB00708,Sufentanil
,29494402,V2,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),l,27.5,213453,DB00708,Sufentanil
,29494402,V2,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),l,47.0,213454,DB00708,Sufentanil
,29494402,V2,"The parameters of the two-compartment pharmacokinetic model for these cardiac outputs were: CL1: 0.9, 1.2, and 1.7 l/min; CL2: 0.9, 3.1, and 6.9 l/min; V1: 1.6, 2.9, and 5.2 l; and V2: 27.5, 47.0, and 79.8 l, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),l,79.8,213455,DB00708,Sufentanil
,29494402,target plasma concentration,"Simulated sufentanil doses to maintain a target plasma concentration of 0.5 ng/ml for 3 h were 99.5, 128.6, and 157.6 μg for cardiac outputs of 3, 5, and 7 l/min, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[ng] / [ml],0,213456,DB00708,Sufentanil
,29494402,target plasma concentration,"Simulated sufentanil doses to maintain a target plasma concentration of 0.5 ng/ml for 3 h were 99.5, 128.6, and 157.6 μg for cardiac outputs of 3, 5, and 7 l/min, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),,128.6,213457,DB00708,Sufentanil
,29494402,target plasma concentration,"Simulated sufentanil doses to maintain a target plasma concentration of 0.5 ng/ml for 3 h were 99.5, 128.6, and 157.6 μg for cardiac outputs of 3, 5, and 7 l/min, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),,157,213458,DB00708,Sufentanil
,29494402,cardiac outputs,"Simulated sufentanil doses to maintain a target plasma concentration of 0.5 ng/ml for 3 h were 99.5, 128.6, and 157.6 μg for cardiac outputs of 3, 5, and 7 l/min, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],3,213459,DB00708,Sufentanil
,29494402,cardiac outputs,"Simulated sufentanil doses to maintain a target plasma concentration of 0.5 ng/ml for 3 h were 99.5, 128.6, and 157.6 μg for cardiac outputs of 3, 5, and 7 l/min, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],5,213460,DB00708,Sufentanil
,29494402,cardiac outputs,"Simulated sufentanil doses to maintain a target plasma concentration of 0.5 ng/ml for 3 h were 99.5, 128.6, and 157.6 μg for cardiac outputs of 3, 5, and 7 l/min, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),[l] / [min],7,213461,DB00708,Sufentanil
,29494402,half-times,"The context-sensitive half-times for these cardiac outputs increased from 3.1 to 19.9 and 25.9 min, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),min,3.1,213462,DB00708,Sufentanil
,29494402,half-times,"The context-sensitive half-times for these cardiac outputs increased from 3.1 to 19.9 and 25.9 min, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),min,19.9,213463,DB00708,Sufentanil
,29494402,half-times,"The context-sensitive half-times for these cardiac outputs increased from 3.1 to 19.9 and 25.9 min, respectively.",Influence of Cardiac Output on the Pharmacokinetics of Sufentanil in Anesthetized Pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29494402/),min,25.9,213464,DB00708,Sufentanil
,31288863,CL,"The parameter estimates of the final model were as follows: CL = 37.8 × EXP (0.207 × (temperature - 36.9)) L h-1, central volume of distribution (V1) = 229 L, V2 = 1640 × (total plasma protein/4.5)2.46 L, and intercompartmental clearance (Q) = 41 L h-1.",Population pharmacokinetics of intravenous sufentanil in critically ill patients supported with extracorporeal membrane oxygenation therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31288863/),[l] / [h],37.8,222287,DB00708,Sufentanil
,31288863,central volume of distribution (V1),"The parameter estimates of the final model were as follows: CL = 37.8 × EXP (0.207 × (temperature - 36.9)) L h-1, central volume of distribution (V1) = 229 L, V2 = 1640 × (total plasma protein/4.5)2.46 L, and intercompartmental clearance (Q) = 41 L h-1.",Population pharmacokinetics of intravenous sufentanil in critically ill patients supported with extracorporeal membrane oxygenation therapy. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31288863/),l,229,222288,DB00708,Sufentanil
,31288863,intercompartmental clearance (Q),"The parameter estimates of the final model were as follows: CL = 37.8 × EXP (0.207 × (temperature - 36.9)) L h-1, central volume of distribution (V1) = 229 L, V2 = 1640 × (total plasma protein/4.5)2.46 L, and intercompartmental clearance (Q) = 41 L h-1.",Population pharmacokinetics of intravenous sufentanil in critically ill patients supported with extracorporeal membrane oxygenation therapy. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31288863/),[l] / [h],41,222289,DB00708,Sufentanil
,2529072,maximal length of effective analgesia,"The mean maximal length of effective analgesia was 4.69 +/- 0.32 hours (mean +/- SEM), whereas the length of effective analgesia with the last dose was only 3.34 +/- 0.46 hours (p less than 0.0005).",Relationship between the pharmacokinetics and the analgesic and respiratory pharmacodynamics of epidural sufentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529072/),h,4.69,224177,DB00708,Sufentanil
,2529072,length of effective analgesia,"The mean maximal length of effective analgesia was 4.69 +/- 0.32 hours (mean +/- SEM), whereas the length of effective analgesia with the last dose was only 3.34 +/- 0.46 hours (p less than 0.0005).",Relationship between the pharmacokinetics and the analgesic and respiratory pharmacodynamics of epidural sufentanil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529072/),h,3.34,224178,DB00708,Sufentanil
,2529072,serum concentration,"Mean serum concentration of sufentanil during periods of slow respiratory rate (0.47 +/- 0.05 ng/ml) was significantly higher than during episodes without adverse respiratory effects (0.37 +/- 0.05 ng/ml, p less than 0.05).",Relationship between the pharmacokinetics and the analgesic and respiratory pharmacodynamics of epidural sufentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529072/),[ng] / [ml],0.47,224179,DB00708,Sufentanil
,2529072,serum concentration,"Mean serum concentration of sufentanil during periods of slow respiratory rate (0.47 +/- 0.05 ng/ml) was significantly higher than during episodes without adverse respiratory effects (0.37 +/- 0.05 ng/ml, p less than 0.05).",Relationship between the pharmacokinetics and the analgesic and respiratory pharmacodynamics of epidural sufentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2529072/),[ng] / [ml],0.37,224180,DB00708,Sufentanil
,8424499,CP50,"The CP50 of sufentanil to suppress responses to intubation, incision, and sternotomy was 7.1 ng/mL and for mediastinal dissection it was 12.7 ng/mL.",Evaluation of sufentanil anesthesia obtained by a computer-controlled infusion for cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424499/),[ng] / [ml],7.1,224338,DB00708,Sufentanil
,8424499,CP50,"The CP50 of sufentanil to suppress responses to intubation, incision, and sternotomy was 7.1 ng/mL and for mediastinal dissection it was 12.7 ng/mL.",Evaluation of sufentanil anesthesia obtained by a computer-controlled infusion for cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8424499/),[ng] / [ml],12.7,224339,DB00708,Sufentanil
,24118506,bioavailability,"The bioavailability of sufentanil and ketamine was 24.6% and 35.8%, respectively.",Intranasal sufentanil/ketamine analgesia in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118506/),%,24.6,229514,DB00708,Sufentanil
,24118506,bioavailability,"The bioavailability of sufentanil and ketamine was 24.6% and 35.8%, respectively.",Intranasal sufentanil/ketamine analgesia in children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118506/),%,35.8,229515,DB00708,Sufentanil
,24118506,Maximum plasma concentration (Cmax),Maximum plasma concentration (Cmax) of sufentanil was 0.042 mcg·l(-1) (coefficient of variation (CV) 12.9%) at 13.8 min (CV 12.4%) (Tmax).,Intranasal sufentanil/ketamine analgesia in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118506/),[mcg] / [l],0.042,229516,DB00708,Sufentanil
,24118506,T,Maximum plasma concentration (Cmax) of sufentanil was 0.042 mcg·l(-1) (coefficient of variation (CV) 12.9%) at 13.8 min (CV 12.4%) (Tmax).,Intranasal sufentanil/ketamine analgesia in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118506/),,13,229517,DB00708,Sufentanil
,24118506,Cmax,"Cmax for ketamine was 0.102 mg·l(-1) (CV 10.8%), and Tmax was 8.5 min (CV 17.3%).",Intranasal sufentanil/ketamine analgesia in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118506/),[mg] / [l],0.102,229518,DB00708,Sufentanil
,24118506,Tmax,"Cmax for ketamine was 0.102 mg·l(-1) (CV 10.8%), and Tmax was 8.5 min (CV 17.3%).",Intranasal sufentanil/ketamine analgesia in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24118506/),min,8.5,229519,DB00708,Sufentanil
,1835321,volume of distribution,"Calculation of pharmacokinetic variables from the derived compartmental models demonstrated an increased volume of distribution of sufentanil in the obese (9098 +/- 2793 mL/kg ideal body weight, mean +/- SD) when compared with a control group (5073 +/- 1673 mL/kg ideal body weight) (P less than 0.01) and a prolonged elimination half-life (208 +/- 82 min vs 135 +/- 42 min, P less than 0.05).",Pharmacokinetics of sufentanil in obese patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835321/),[ml] / [kg],9098,230270,DB00708,Sufentanil
,1835321,volume of distribution,"Calculation of pharmacokinetic variables from the derived compartmental models demonstrated an increased volume of distribution of sufentanil in the obese (9098 +/- 2793 mL/kg ideal body weight, mean +/- SD) when compared with a control group (5073 +/- 1673 mL/kg ideal body weight) (P less than 0.01) and a prolonged elimination half-life (208 +/- 82 min vs 135 +/- 42 min, P less than 0.05).",Pharmacokinetics of sufentanil in obese patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835321/),[ml] / [kg],5073,230271,DB00708,Sufentanil
,1835321,elimination half-life,"Calculation of pharmacokinetic variables from the derived compartmental models demonstrated an increased volume of distribution of sufentanil in the obese (9098 +/- 2793 mL/kg ideal body weight, mean +/- SD) when compared with a control group (5073 +/- 1673 mL/kg ideal body weight) (P less than 0.01) and a prolonged elimination half-life (208 +/- 82 min vs 135 +/- 42 min, P less than 0.05).",Pharmacokinetics of sufentanil in obese patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835321/),min,208,230272,DB00708,Sufentanil
,1835321,elimination half-life,"Calculation of pharmacokinetic variables from the derived compartmental models demonstrated an increased volume of distribution of sufentanil in the obese (9098 +/- 2793 mL/kg ideal body weight, mean +/- SD) when compared with a control group (5073 +/- 1673 mL/kg ideal body weight) (P less than 0.01) and a prolonged elimination half-life (208 +/- 82 min vs 135 +/- 42 min, P less than 0.05).",Pharmacokinetics of sufentanil in obese patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835321/),min,135,230273,DB00708,Sufentanil
,1835321,plasma clearance,"In contrast, plasma clearance was similar in both obese and control groups (32.9 +/- 12.5 vs 26.4 +/- 5.7 mL/kg ideal body weight).",Pharmacokinetics of sufentanil in obese patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835321/),[ml] / [kg],32.9,230274,DB00708,Sufentanil
,1835321,plasma clearance,"In contrast, plasma clearance was similar in both obese and control groups (32.9 +/- 12.5 vs 26.4 +/- 5.7 mL/kg ideal body weight).",Pharmacokinetics of sufentanil in obese patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1835321/),[ml] / [kg],26.4,230275,DB00708,Sufentanil
,6226471,apparent volume of distribution (area),"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),l,60,233049,DB00708,Sufentanil
,6226471,apparent volume of distribution (area),"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),l,300,233050,DB00708,Sufentanil
,6226471,terminal half-life,"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),h,1.5 to 6,233051,DB00708,Sufentanil
,6226471,terminal half-life,"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),h,15,233052,DB00708,Sufentanil
,6226471,total body clearance,"Hence, estimates of apparent volume of distribution (area) range from around 60L to over 300L, estimates of terminal half-life range from about 1.5 to 6 hours (15 hours in geriatric patients) and total body clearance ranges from 0.4 to over 1.5 L/min.",Clinical pharmacokinetics of fentanyl and its newer derivatives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6226471/),[l] / [min],0.4 to over 1.5,233053,DB00708,Sufentanil
,23958818,CL1,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),[l] / [min],1.01,234602,DB00708,Sufentanil
,23958818,V1,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),l,3.35,234603,DB00708,Sufentanil
,23958818,CL2,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),[l] / [min],1.47,234604,DB00708,Sufentanil
,23958818,V2,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),l,13.9,234605,DB00708,Sufentanil
,23958818,CL3,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),[l] / [min],1.41,234606,DB00708,Sufentanil
,23958818,V3,"The final estimates of the model parameters for the typical adult patient (67 yr old, weighing 70 kg) undergoing cardiac surgery were as follows: CL1 = 1.01 l/min, V1 = 3.35 l, CL2 = 1.47 l/min, V2 = 13.9 l, CL3 = 1.41 l/min, and V3 = 145 l.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),l,145,234607,DB00708,Sufentanil
,23958818,half-time,"The elimination clearance decreased by 43% between the age of 40 and 80 yr, and simulations demonstrated that context-sensitive half-time increased from 26 to 84 min in 40- and 80-yr-old subjects, respectively.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),min,26,234608,DB00708,Sufentanil
,23958818,half-time,"The elimination clearance decreased by 43% between the age of 40 and 80 yr, and simulations demonstrated that context-sensitive half-time increased from 26 to 84 min in 40- and 80-yr-old subjects, respectively.",Population pharmacokinetic modeling of hydromorphone in cardiac surgery patients during postoperative pain therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23958818/),min,84,234609,DB00708,Sufentanil
,31231918,ED50,"The ED50 of propofol was 1.651 mg/kg (95% CI, 1.561-1.722 mg/kg) in Group A and 1.991 mg/kg (95% CI, 1.902-2.081 mg/kg) in Group B.",ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31231918/),[mg] / [kg],1.651,235173,DB00708,Sufentanil
,31231918,ED50,"The ED50 of propofol was 1.651 mg/kg (95% CI, 1.561-1.722 mg/kg) in Group A and 1.991 mg/kg (95% CI, 1.902-2.081 mg/kg) in Group B.",ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31231918/),[mg] / [kg],1.991,235174,DB00708,Sufentanil
,31231918,ED95,"The ED95 of propofol was 1.827 mg/kg (95% CI, 1.746-2.236 mg/kg) in Group A and 2.153 mg/kg (95% CI, 2.070-2.73 7 mg/kg) in Group B.",ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31231918/),[mg] / [kg],1.827,235175,DB00708,Sufentanil
,31231918,ED95,"The ED95 of propofol was 1.827 mg/kg (95% CI, 1.746-2.236 mg/kg) in Group A and 2.153 mg/kg (95% CI, 2.070-2.73 7 mg/kg) in Group B.",ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31231918/),[mg] / [kg],2.153,235176,DB00708,Sufentanil
,31231918,ED50,"The ED50 values for propofol when co-administered with low-dose sufentanil for intravenous anaesthesia in hysteroscopy were 1.651 mg/kg (sufentanil 0.2 μg/kg) and 1.991 mg/kg (sufentanil 0.1 μg/kg). (www.chictr.org.cn, registration number: ChiCTR1900021224).",ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31231918/),[mg] / [kg],1.651,235177,DB00708,Sufentanil
,31231918,ED50,"The ED50 values for propofol when co-administered with low-dose sufentanil for intravenous anaesthesia in hysteroscopy were 1.651 mg/kg (sufentanil 0.2 μg/kg) and 1.991 mg/kg (sufentanil 0.1 μg/kg). (www.chictr.org.cn, registration number: ChiCTR1900021224).",ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31231918/),[mg] / [kg],1.991,235178,DB00708,Sufentanil
,8447208,elimination half-life,"The overall mean elimination half-life was 182 min, Vdss 169 l and the plasma clearance 910 ml min-1.",Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447208/),min,182,240009,DB00708,Sufentanil
,8447208,Vdss,"The overall mean elimination half-life was 182 min, Vdss 169 l and the plasma clearance 910 ml min-1.",Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447208/),l,169,240010,DB00708,Sufentanil
,8447208,plasma clearance,"The overall mean elimination half-life was 182 min, Vdss 169 l and the plasma clearance 910 ml min-1.",Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8447208/),[ml] / [min],910,240011,DB00708,Sufentanil
,10702452,drug,The drug infusion rates (range of means: 5.4-5. 9 mL/h) were similar in all patients.,What concentration of sufentanil should be combined with ropivacaine 0.2% wt/vol for postoperative patient-controlled epidural analgesia? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702452/),[ml] / [h],5.4-5. 9,243262,DB00708,Sufentanil
,10702452,infusion rates,The drug infusion rates (range of means: 5.4-5. 9 mL/h) were similar in all patients.,What concentration of sufentanil should be combined with ropivacaine 0.2% wt/vol for postoperative patient-controlled epidural analgesia? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702452/),[ml] / [h],5.4-5. 9,243263,DB00708,Sufentanil
,29451620,time to patient extubation,"Propofol target-controlled infusion was discontinued when orotracheal extubation was indicated, and the time to patient extubation was significantly higher in the hypothermic on-pump group than in the off-pump group (459 versus 273 min, p=0.0048).",Application of a pharmacokinetics-pharmacodynamics approach to the free propofol plasma levels during coronary artery bypass grafting surgery with hypothermic cardiopulmonary bypass. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29451620/),min,459,243502,DB00708,Sufentanil
,29451620,time to patient extubation,"Propofol target-controlled infusion was discontinued when orotracheal extubation was indicated, and the time to patient extubation was significantly higher in the hypothermic on-pump group than in the off-pump group (459 versus 273 min, p=0.0048).",Application of a pharmacokinetics-pharmacodynamics approach to the free propofol plasma levels during coronary artery bypass grafting surgery with hypothermic cardiopulmonary bypass. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29451620/),min,273,243503,DB00708,Sufentanil
,21079936,plasma concentration of ropivacaine at the end of epidural infusion (C(48 h)),Mean plasma concentration of ropivacaine at the end of epidural infusion (C(48 h)) was 1.69 μg/mL (0.21-3.8 μg/mL).,Flip-flop kinetics of ropivacaine during continuous epidural infusion influences its accumulation rate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079936/),[μg] / [ml],1.69,243995,DB00708,Sufentanil
,21079936,C(max),"Mean (range) C(max) was 1.82 μg/mL (0.61-4.0 μg/mL); the area under the plasma concentration curve, AUC ((0-60)), was 67.48 ± 30.60 μg·h/mL.",Flip-flop kinetics of ropivacaine during continuous epidural infusion influences its accumulation rate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079936/),[μg] / [ml],1.82,243996,DB00708,Sufentanil
,21079936,"area under the plasma concentration curve, AUC ((0-60))","Mean (range) C(max) was 1.82 μg/mL (0.61-4.0 μg/mL); the area under the plasma concentration curve, AUC ((0-60)), was 67.48 ± 30.60 μg·h/mL.",Flip-flop kinetics of ropivacaine during continuous epidural infusion influences its accumulation rate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079936/),[h·μg] / [ml],67.48,243997,DB00708,Sufentanil
,21079936,clearance,Mean clearance for total ropivacaine was 5.33 L/h.,Flip-flop kinetics of ropivacaine during continuous epidural infusion influences its accumulation rate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079936/),[l] / [h],5.33,243998,DB00708,Sufentanil
,21079936,volume of distribution (Vd),The volume of distribution (Vd) was 92.15 L.,Flip-flop kinetics of ropivacaine during continuous epidural infusion influences its accumulation rate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079936/),l,92.15,243999,DB00708,Sufentanil
,21079936,half-life (t(1/2,"The infusion dosing period half-life (t(1/2,DP)=0.693 × Vd/CL) was 10.8 h.",Flip-flop kinetics of ropivacaine during continuous epidural infusion influences its accumulation rate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21079936/),h,10.8,244000,DB00708,Sufentanil
,9141924,hepatic extraction coefficient,The hepatic extraction coefficient was 0.14 for alfentanil and 0.35 for sufentanil.,Hepatic disposition of alfentanil and sufentanil in patients undergoing orthotopic liver transplantation. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9141924/),,0.14,249908,DB00708,Sufentanil
,9141924,hepatic extraction coefficient,The hepatic extraction coefficient was 0.14 for alfentanil and 0.35 for sufentanil.,Hepatic disposition of alfentanil and sufentanil in patients undergoing orthotopic liver transplantation. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9141924/),,0.35,249909,DB00708,Sufentanil
,7893025,time to peak CSF sufentanil concentration,The time to peak CSF sufentanil concentration differed (P < 0.01) after epidural administration in the lumbar (0.76 +/- 0.50 h) and thoracic (2.1 +/- 1.4 h) region.,The cerebrospinal fluid and plasma pharmacokinetics of sufentanil after thoracic or lumbar epidural administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893025/),h,0.76,259456,DB00708,Sufentanil
,7893025,time to peak CSF sufentanil concentration,The time to peak CSF sufentanil concentration differed (P < 0.01) after epidural administration in the lumbar (0.76 +/- 0.50 h) and thoracic (2.1 +/- 1.4 h) region.,The cerebrospinal fluid and plasma pharmacokinetics of sufentanil after thoracic or lumbar epidural administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893025/),h,2.1,259457,DB00708,Sufentanil
,7893025,CSF/plasma concentration-ratio,"The decline in sufentanil concentration was more rapid in CSF than plasma; in the lumbar group the CSF/plasma concentration-ratio was eight and five at 6 and 10 h, respectively, after sufentanil administration.",The cerebrospinal fluid and plasma pharmacokinetics of sufentanil after thoracic or lumbar epidural administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893025/),,eight,259458,DB00708,Sufentanil
,7893025,CSF/plasma concentration-ratio,"The decline in sufentanil concentration was more rapid in CSF than plasma; in the lumbar group the CSF/plasma concentration-ratio was eight and five at 6 and 10 h, respectively, after sufentanil administration.",The cerebrospinal fluid and plasma pharmacokinetics of sufentanil after thoracic or lumbar epidural administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7893025/),,five,259459,DB00708,Sufentanil
,8273922,Time to extubation,Time to extubation was the same in both groups (301 +/- 141 and 307 +/- 148 min).,[Peroperative perfusion of fentanyl or sufentanil: plasma concentrations and postoperative respiratory changes]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8273922/),min,301,262732,DB00708,Sufentanil
,8273922,Time to extubation,Time to extubation was the same in both groups (301 +/- 141 and 307 +/- 148 min).,[Peroperative perfusion of fentanyl or sufentanil: plasma concentrations and postoperative respiratory changes]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8273922/),min,307,262733,DB00708,Sufentanil
,8273922,plasma concentrations,"At the time, plasma concentrations of F and S were 1.35 +/- 0.9 ng.",[Peroperative perfusion of fentanyl or sufentanil: plasma concentrations and postoperative respiratory changes]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8273922/),ng,1.35,262734,DB00708,Sufentanil
,8273922,elimination half-life,No similar peaks occurred in group S. Mean elimination half-life was shorter with sufentanil (457 +/- 130 min) than with fentanyl (325 +/- 132 min) (not significant).,[Peroperative perfusion of fentanyl or sufentanil: plasma concentrations and postoperative respiratory changes]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8273922/),min,457,262735,DB00708,Sufentanil
,8273922,elimination half-life,No similar peaks occurred in group S. Mean elimination half-life was shorter with sufentanil (457 +/- 130 min) than with fentanyl (325 +/- 132 min) (not significant).,[Peroperative perfusion of fentanyl or sufentanil: plasma concentrations and postoperative respiratory changes]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8273922/),min,325,262736,DB00708,Sufentanil
,7902033,Total clearance,Total clearance (250-300 l/h) of remifentanil was independent of dose and was approximately three to four times greater than the normal hepatic blood flow.,Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),[l] / [h],250-300,266515,DB00708,Sufentanil
,7902033,Volume of distribution at steady state,Volume of distribution at steady state (25-40 l) also was independent of dose.,Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),l,25-40,266516,DB00708,Sufentanil
,7902033,terminal half-life,The terminal half-life of remifentanil ranged from 10 to 21 min.,Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,10 to 21,266517,DB00708,Sufentanil
,7902033,time,"The time required for a 50% reduction in the effect site concentration of remifentanil (3.65 min) was considerably less than that for sufentanil (33.9 min), alfentanil (58.5 min), and fentanyl (262 min).",Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,3.65,266518,DB00708,Sufentanil
,7902033,time,"The time required for a 50% reduction in the effect site concentration of remifentanil (3.65 min) was considerably less than that for sufentanil (33.9 min), alfentanil (58.5 min), and fentanyl (262 min).",Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,33.9,266519,DB00708,Sufentanil
,7902033,time,"The time required for a 50% reduction in the effect site concentration of remifentanil (3.65 min) was considerably less than that for sufentanil (33.9 min), alfentanil (58.5 min), and fentanyl (262 min).",Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,58.5,266520,DB00708,Sufentanil
,7902033,time,"The time required for a 50% reduction in the effect site concentration of remifentanil (3.65 min) was considerably less than that for sufentanil (33.9 min), alfentanil (58.5 min), and fentanyl (262 min).",Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,262,266521,DB00708,Sufentanil
,7902033,terminal half-life,The mean terminal half-life of GI90291 ranged from 88 to 137 min.,Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7902033/),min,88 to 137,266522,DB00708,Sufentanil
,6238552,half-lives,"In 9 of the 10 patients, a tri-exponential equation optimally described the sufentanil concentration decay curve, with average (+/-SEM) half-lives for the rapid (pi) and slow (alpha) distribution phases of 1.4 +/- 0.3 min and 17.7 +/- 2.6 min, respectively.",The pharmacokinetics of sufentanil in surgical patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238552/),min,1.4,266688,DB00708,Sufentanil
,6238552,half-lives,"In 9 of the 10 patients, a tri-exponential equation optimally described the sufentanil concentration decay curve, with average (+/-SEM) half-lives for the rapid (pi) and slow (alpha) distribution phases of 1.4 +/- 0.3 min and 17.7 +/- 2.6 min, respectively.",The pharmacokinetics of sufentanil in surgical patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238552/),min,17.7,266689,DB00708,Sufentanil
,6238552,terminal elimination (beta) half-life,The average terminal elimination (beta) half-life was 164 +/- 22 min.,The pharmacokinetics of sufentanil in surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238552/),min,164,266690,DB00708,Sufentanil
,6238552,Vd beta,"The average value for Vd beta was 2.9 +/- 0.2 1/kg, Vdss 1.7 +/- 0.2 1/kg and total plasma clearance 12.7 +/- 0.8 ml X kg-1 X min-1 (935 +/- 50 ml/min).",The pharmacokinetics of sufentanil in surgical patients. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238552/),[1] / [kg],2.9,266691,DB00708,Sufentanil
,6238552,Vdss,"The average value for Vd beta was 2.9 +/- 0.2 1/kg, Vdss 1.7 +/- 0.2 1/kg and total plasma clearance 12.7 +/- 0.8 ml X kg-1 X min-1 (935 +/- 50 ml/min).",The pharmacokinetics of sufentanil in surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238552/),[1] / [kg],1.7,266692,DB00708,Sufentanil
,6238552,total plasma clearance,"The average value for Vd beta was 2.9 +/- 0.2 1/kg, Vdss 1.7 +/- 0.2 1/kg and total plasma clearance 12.7 +/- 0.8 ml X kg-1 X min-1 (935 +/- 50 ml/min).",The pharmacokinetics of sufentanil in surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238552/),[ml] / [kg·min],12.7,266693,DB00708,Sufentanil
,6238552,total plasma clearance,"The average value for Vd beta was 2.9 +/- 0.2 1/kg, Vdss 1.7 +/- 0.2 1/kg and total plasma clearance 12.7 +/- 0.8 ml X kg-1 X min-1 (935 +/- 50 ml/min).",The pharmacokinetics of sufentanil in surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238552/),[ml] / [min],935,266694,DB00708,Sufentanil
,6238552,distribution half-life,"In one patient, a bi-exponential equation was sufficient to describe the concentration-time data, yielding a distribution half-life of 4.7 min and an elimination half-life of 117 min.",The pharmacokinetics of sufentanil in surgical patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238552/),min,4.7,266695,DB00708,Sufentanil
,6238552,elimination half-life,"In one patient, a bi-exponential equation was sufficient to describe the concentration-time data, yielding a distribution half-life of 4.7 min and an elimination half-life of 117 min.",The pharmacokinetics of sufentanil in surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6238552/),min,117,266696,DB00708,Sufentanil
,3512140,elimination half-life,Its elimination half-life is 149 minutes and its clearance is 11.3 ml/min/kg.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,149,268206,DB00708,Sufentanil
,3512140,clearance,Its elimination half-life is 149 minutes and its clearance is 11.3 ml/min/kg.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),[ml] / [kg·min],11.3,268207,DB00708,Sufentanil
,3512140,elimination half-life,"Its distribution and redistribution are rapid, with an elimination half-life of 83 to 137 minutes and a clearance of 4.37 to 6.47 ml/min/kg in adult patients.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,83 to 137,268208,DB00708,Sufentanil
,3512140,clearance,"Its distribution and redistribution are rapid, with an elimination half-life of 83 to 137 minutes and a clearance of 4.37 to 6.47 ml/min/kg in adult patients.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),[ml] / [kg·min],4.37 to 6.47,268209,DB00708,Sufentanil
,3512140,distribution,"Etomidate, a carboxylated imidazole, is rapidly distributed within a central compartment and then to peripheral compartments; its slow distribution and terminal elimination half-lives are 28 and 273 to 330 minutes, respectively, and its clearance (11.6 to 25 ml/min/kg) is equal to its hepatic plasma flow.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,28,268210,DB00708,Sufentanil
,3512140,terminal elimination half-lives,"Etomidate, a carboxylated imidazole, is rapidly distributed within a central compartment and then to peripheral compartments; its slow distribution and terminal elimination half-lives are 28 and 273 to 330 minutes, respectively, and its clearance (11.6 to 25 ml/min/kg) is equal to its hepatic plasma flow.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,273 to 330,268211,DB00708,Sufentanil
,3512140,clearance,"Etomidate, a carboxylated imidazole, is rapidly distributed within a central compartment and then to peripheral compartments; its slow distribution and terminal elimination half-lives are 28 and 273 to 330 minutes, respectively, and its clearance (11.6 to 25 ml/min/kg) is equal to its hepatic plasma flow.",Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),[ml] / [kg·min],11.6 to 25,268212,DB00708,Sufentanil
,3512140,half-life,Distribution is rapid with a mean half-life of 2.1 minutes and an elimination half-life of 47 minutes.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,2.1,268213,DB00708,Sufentanil
,3512140,elimination half-life,Distribution is rapid with a mean half-life of 2.1 minutes and an elimination half-life of 47 minutes.,Clinical pharmacokinetics of the newer intravenous anaesthetic agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3512140/),min,47,268214,DB00708,Sufentanil
,15448532,duration of analgesia (mesor),Rhythm analysis revealed a mean ( +/- SD) duration of analgesia (mesor) of 93.0 +/- 3.8 min.,Chronopharmacology of intrathecal sufentanil for labor analgesia: daily variations in duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15448532/),min,93.0,268775,DB00708,Sufentanil
,15448532,amplitude,The amplitude of this 12-h component was 16.1 +/- 5.5 min.,Chronopharmacology of intrathecal sufentanil for labor analgesia: daily variations in duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15448532/),min,16.1,268776,DB00708,Sufentanil
,30632944,volume of distribution,We observed increased sufentanil volume of distribution (11.6 vs 5.6 L/kg) and decreased sufentanil clearance (0.535 vs 0.746 L/h/kg) in extracorporeal membrane oxygenation period.,Sufentanil pharmacokinetics in a full-term neonate treated with extracorporeal membrane oxygenation: a case report. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632944/),[l] / [kg],11.6,273409,DB00708,Sufentanil
,30632944,volume of distribution,We observed increased sufentanil volume of distribution (11.6 vs 5.6 L/kg) and decreased sufentanil clearance (0.535 vs 0.746 L/h/kg) in extracorporeal membrane oxygenation period.,Sufentanil pharmacokinetics in a full-term neonate treated with extracorporeal membrane oxygenation: a case report. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632944/),[l] / [kg],5.6,273410,DB00708,Sufentanil
,30632944,clearance,We observed increased sufentanil volume of distribution (11.6 vs 5.6 L/kg) and decreased sufentanil clearance (0.535 vs 0.746 L/h/kg) in extracorporeal membrane oxygenation period.,Sufentanil pharmacokinetics in a full-term neonate treated with extracorporeal membrane oxygenation: a case report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632944/),[l] / [h·kg],0.535,273411,DB00708,Sufentanil
,30632944,clearance,We observed increased sufentanil volume of distribution (11.6 vs 5.6 L/kg) and decreased sufentanil clearance (0.535 vs 0.746 L/h/kg) in extracorporeal membrane oxygenation period.,Sufentanil pharmacokinetics in a full-term neonate treated with extracorporeal membrane oxygenation: a case report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30632944/),[l] / [h·kg],0.746,273412,DB00708,Sufentanil
